Publications

Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Vizio DD, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. bioRxiv [Preprint]. 2023 Oct 12:2023.09.28.560025. doi: 10.1101/2023.09.28.560025. PMID: 37905039; PMCID: PMC10614109.

Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O'Brien VP, Isaacs WB, Epstein JI, De Marzo AM, Trock BJ, Luo J, Brennen WN, Tretiakova M, Vakar-Lopez F, True LD, Goodrich DW, Corey E, Morrissey C, Nelson PS, Hurley PJ, Gulati R, Haffner MC. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. J Pathol. 2023 Oct 18. doi: 10.1002/path.6216. Epub ahead of print. PMID: 37850574.

Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK. Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers. Cancer Res Commun. 2023 Oct 12. doi: 10.1158/2767-9764.CRC-23-0250. Epub ahead of print. PMID: 37823778; PMCID: PMC10658857.

Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, Morrissey C. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Prostate. 2023 Oct 5. doi: 10.1002/pros.24630. Epub ahead of print. PMID: 37796107.

Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A 3rd, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, Alumkal JJ. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. JCI Insight. 2023 Aug 8;8(15):e167440. doi: 10.1172/jci.insight.167440. PMID: 37440313; PMCID: PMC10445684.

Nyquist MD, Coleman IM, Lucas JM, Li D, Hanratty B, Meade H, Mostaghel EA, Plymate SR, Corey E, Haffner MC, Nelson PS. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex. Cancer Res. 2023 Jun 23:CAN-22-2613. doi: 10.1158/0008-5472.CAN-22-2613. PMID: 37352376.

Gritsina G, Fong KW, Lu X, Lin Z, Xie W, Agarwal S, Lin D, Schiltz GE, Beltran H, Corey E, Morrissey C, Wang Y, Zhao JC, Hussain M, Yu J. Chemokine receptor CXCR7 activates AURKA and promotes neuroendocrine prostate cancer growth. J Clin Invest. 2023 Jun 22:e166248. doi: 10.1172/JCI166248. PMID: 37347559.

Patel P, Harmon S, Iseman R, Ludkowski O, Auman H, Hawley S, Newcomb LF, Lin DW, Nelson PS, Feng Z, Boyer HD, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Cooperberg MR, Chan E, Simko J, Fazli L, Gleave M, Hurtado-Coll A, Thompson IM, Troyer D, McKenney JK, Wei W, Choyke PL, Bratslavsky G, Turkbey B, Siemens DR, Squire J, Peng YP, Brooks JD, Jamaspishvili T. Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: a Multi-Center Retrospective Study. Mod Pathol. 2023 Jun 19:100241. doi: 10.1016/j.modpat.2023.100241. PMID: 37343766.

Zaalberg A, Minnee E, Mayayo-Peralta I, Schuurman K, Gregoricchio S, van Schaik TA, Hoekman L, Li D, Corey E, Janssen H, Lieftink C, Prekovic S, Altelaar M, Nelson PS, Beijersbergen RL, Zwart W, Bergman A. A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator. bioRxiv [Preprint]. 2023 Jun 7:2023.06.06.543873. doi: 10.1101/2023.06.06.543873. PMID: 37333335; PMCID: PMC10274642.

Ghali F, Vakar-Lopez F, Roudier MP, Garcia J, Arora S, Cheng HH, Schweizer MT, Haffner MC, Lee JK, Yu EY, Grivas P, Montgomery B, Hsieh AC, Wright JL, Lam HM. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study. Clin Genitourin Cancer. 2023 May 25:S1558-7673(23)00132-5. doi: 10.1016/j.clgc.2023.05.014. PMID: 37344281.

Serafin R, Koyuncu C, Xie W, Huang H, Glaser AK, Reder NP, Janowczyk A, True LD, Madabhushi A, Liu JT. Nondestructive 3D pathology with analysis of nuclear features for prostate cancer risk assessment. J Pathol. 2023 May 26. doi: 10.1002/path.6090. PMID: 37232213.

Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, Sun H, Javier G, Nutt S, Coleman I, Hitchcock L, Zhang A, Rudoy D, Gulati R, Patel RA, Roudier MP, True LD, Srivastava S, Morrissey CM, Haffner MC, Nelson PS, Priceman SJ, Ishihara J, Lee JK. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023 Apr 11;14(1):2041. doi: 10.1038/s41467-023-37874-2. PMID: 37041154; PMCID: PMC10090190.

De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. Cancer Discov. 2023 Mar 1;13(3):632-653. doi: 10.1158/2159-8290.CD-22-0692. PMID: 36399432; PMCID: PMC9976992.

Bae SY, Bergom HE, Day A, Greene JT, Sychev ZE, Larson G, Corey E, Plymate SR, Freedman TS, Hwang JH, Drake JM. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer. Front Endocrinol (Lausanne). 2023 Mar 29;14:1093332. doi: 10.3389/fendo.2023.1093332. PMID: 37065756; PMCID: PMC10090553.

Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C. LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer. Cancer Res. 2023 Mar 6:CAN-22-2433. doi: 10.1158/0008-5472.CAN-22-2433. PMID: 36877164.

Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):194-200. doi: 10.1038/s41391-022-00636-0. Epub 2022 Dec 23. PMID: 36564459; PMCID: PMC10286318.

Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023 Feb 23:e162907. doi: 10.1172/jci.insight.162907. PMID: 36821396.

Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. The future of patient-derived xenografts in prostate cancer research. Nat Rev Urol. 2023 Jan 17. doi: 10.1038/s41585-022-00706-x. PMID: 36650259.

Austin EJ, Kilgore MR, Ko CW, Parker EU, Alvarez R, Koch LK, Donlan AW, Lee JM, Flanagan MR, DeStefano LM, Javid SH, Gore JL. Multi-pilot implementation experiences of patient-centered pathology reports: lessons learned for the advancement of patient-centered tools for cancer decision-making. Cancer Causes Control. 2023 Apr;34(4):399-406. doi: 10.1007/s10552-023-01669-z. Epub 2023 Jan 25. PMID: 36695825.

Montgomery B, Mostaghel EA. Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full? Eur Urol. 2023 Jan 27:S0302-2838(23)00057-X. doi: 10.1016/j.eururo.2023.01.021. PMID: 36710203.

Klein EA, Beer TM, Seiden M. The Promise of Multicancer Early Detection. Am J Med. 2023 Mar;136(3):e46-e47. doi: 10.1016/j.amjmed.2022.05.016. PMID: 36796953.

Pinsky P, Lange J, Etzioni R. Estimating stage-specific sensitivity for cancer screening tests. J Med Screen. 2023 Feb 3:9691413231154801. doi: 10.1177/09691413231154801. PMID: 36734139.

Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene. 2023 Mar;42(12):926-937. doi: 10.1038/s41388-023-02604-x. Epub 2023 Feb 1. PMID: 36725887.

Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, Wright J. Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial. J Urol. 2023 Feb;209(2):354-363. doi: 10.1097/JU.0000000000003038. Epub 2023 Feb 1. PMID: 36621991; PMCID: PMC9833838

Devasia TP, Mariotto AB, Nyame YA, Etzioni R. Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2023 Jan 30:EPI-22-1038. doi: 10.1158/1055-9965.EPI-22-1038. Epub ahead of print. PMID: 36716178.

Nyame YA, Holt SK, Etzioni RD, Gore JL. Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer. Cancer. 2023 Feb 13. doi: 10.1002/cncr.34681. PMID: 36776124.

Graham LS, Haffner MC, Sayar E, Gawne A, Schweizer MT, Pritchard CC, Coleman I, Nelson PS, Yu EY. Clinical, pathologic, and molecular features of amphicrine prostate cancer. Prostate. 2023 Feb 13. doi: 10.1002/pros.24497. PMID: 36779357.

Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B. Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104. PMID: 36623239

Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. PMID: 36609003

Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, Shariat SF. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nat Rev Urol. 2023 Jan 4. doi: 10.1038/s41585-022-00680-4. PMID: 36600087.

Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN Jr, Evans CP, Hammock BD, Liu C. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 Jan 3. doi: 10.1038/s41388-022-02566-6. PMID: 36596844.

Schweizer MT, Gulati R, Yezefski T, Cheng HH, Mostaghel E, Haffner MC, Patel RA, De Sarkar N, Ha G, Dumpit R, Woo B, Lin A, Panlasigui P, McDonald N, Lai M, Nega K, Hammond J, Grivas P, Hsieh A, Montgomery B, Nelson PS, Yu EY. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022 Dec 23. doi: 10.1038/s41391-022-00636-0. PMID: 36564459

Makrakis D, Wright JL, Roudier MP, Garcia J, Vakar-Lopez F, Porter MP, Wang Y, Dash A, Lin D, Schade G, Winters B, Zhang X, Nelson P, Mostaghel E, Cheng HH, Schweizer M, Holt SK, Gore JL, Yu EY, Lam HM, Montgomery B. A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2022 Dec 23:S1558-7673(22)00261-0. doi: 10.1016/j.clgc.2022.12.003. Epub ahead of print. PMID: 36710146.

Ghali F, Zhao Y, Patel D, Jewell T, Yu EY, Grivas P, Montgomery RB, Gore JL, Etzioni RB, Wright JL. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. Eur Urol Open Sci. 2022 Dec 15;47:58-64. doi: 10.1016/j.euros.2022.11.003. PMID: 36601043; PMCID: PMC9806712.

DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sjöström M, Zhu X, Corey E, Feng FY, Zhou W, Fatatis A. IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. Cancer Res Commun. 2022 Dec;2(12):1545-1557. doi: 10.1158/2767-9764.crc-22-0262. PMID: 36561929; PMCID: PMC9770512

Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, Chan N, Ung L, Altıntaş UB, Bui JM, Wang Y, Fazli L, Oo HZ, Rennie PS, Lack NA, Cherkasov A, Gleave ME, Gsponer J, Lallous N. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. Nucleic Acids Res. 2022 Dec 20:gkac1158. doi: 10.1093/nar/gkac1158. PMID: 36535377

Lin DW. Point-Counterpoint: Active Surveillance Should Still Be Preferred Management for All (or Nearly All) Men With Low-risk Prostate Cancer. J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134. PMID: 36573929

Germanos AA, Arora S, Zheng Y, Goddard ET, Coleman IM, Ku AT, Wilkinson S, Song H, Brady NJ, Amezquita RA, Zager M, Long A, Yang YC, Bielas JH, Gottardo R, Rickman DS, Huang FW, Ghajar CM, Nelson PS, Sowalsky AG, Setty M, Hsieh AC. Defining cellular population dynamics at single-cell resolution during prostate cancer progression. Elife. 2022 Dec 13;11:e79076. doi: 10.7554/eLife.79076. PMID: 36511483; PMCID: PMC9747158

Doebley AL, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, Hiatt JB, Patton RD, De Sarkar N, Collier KA, Hoge ACH, Chen K, Zimmer A, Weber ZT, Adil M, Reichel JB, Polak P, Adalsteinsson VA, Nelson PS, MacPherson D, Parsons HA, Stover DG, Ha G. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat Commun. 2022 Dec 3;13(1):7475. doi: 10.1038/s41467-022-35076-w. PMID: 36463275; PMCID: PMC9719521

Arman T, Nelson PS. Endocrine and paracrine characteristics of neuroendocrine prostate cancer. Front Endocrinol (Lausanne). 2022 Nov 11;13:1012005. doi: 10.3389/fendo.2022.1012005. PMID: 36440195; PMCID: PMC9691667

Clark NM, Roberts EA, Federenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR. ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Ann Surg Oncol. 2022 Nov 22. doi: 10.1245/s10434-022-12800-w. PMID: 36414905

Quaglia F, Krishn SR, Sossey-Alaoui K, Rana PS, Pluskota E, Park PH, Shields CD, Lin S, McCue P, Kossenkov AV, Wang Y, Goodrich DW, Ku SY, Beltran H, Kelly WK, Corey E, Klose M, Bandtlow C, Liu Q, Altieri DC, Plow EF, Languino LR. The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 Nov 7;12(1):18879. doi: 10.1038/s41598-022-21711-5. PMID: 36344556

De Sarkar N, Patton RD, Doebley AL, Hanratty B, Adil M, Kreitzman AJ, Sarthy JF, Ko M, Brahma S, Meers MP, Janssens DH, Ang LS, Coleman IM, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Cancer Discov. 2022 Nov 18:CD-22-0692. doi: 10.1158/2159-8290.CD-22-0692. Online ahead of print. PMID: 36399432

Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.Prostate. 2022 Nov 16. doi: 10.1002/pros.24454. Online ahead of print. PMID: 36382533

Vasciaveo A, Arriaga JM, Nunes de Almeida F, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, Califano A, Abate-Shen C. OncoLoop: A network-based precision cancer medicine framework.  Cancer Discov. 2022 Nov 14:CD-22-0342. doi: 10.1158/2159-8290.CD-22-0342. Online ahead of print. PMID: 36374194

Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, Denmeade S, Carducci M, Eisenberger M, DeWeese TL, Orton M, Deville C, Davicioni E, Liauw SL, Heath EI, Greco S, Desai NB, Spratt DE, Feng F, Wang H, Beer TM, Antonarakis ES. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2022 Nov 11:JCO2201662. doi: 10.1200/JCO.22.01662. Online ahead of print. PMID: 36367998

Jia D, Zhou Z, Kwon OJ, Zhang L, Wei X, Zhang Y, Yi M, Roudier MP, Regier MC, Dumpit R, Nelson PS, Headley M, True L, Lin DW, Morrissey C, Creighton CJ, Xin L. Stromal FOXF2 suppresses prostate cancer progression and metastasis by enhancing antitumor immunity. Nat Commun. 2022 Nov 11;13(1):6828. doi: 10.1038/s41467-022-34665-z. PMID: 36369237

Lee YC, Lam HM, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol. 2022 Sep;19(9):515-533. doi: 10.1038/s41585-022-00608-y. PMID: 35764795.

Berchuck JE, Facchinetti F, DiToro DF, Baiev I, Majeed U, Reyes S, Chen C, Zhang K, Sharman R, Junior PLSU, Maurer J, Shroff RT, Pritchard CC, Wu MJ, Catenacci DVT, Javle M, Friboulet L, Hollebecque A, Bardeesy N, Zhu AX, Lennerz JK, Tan B, Borad M, Parikh AR, Kiedrowski LA, Kelley RK, Mody K, Juric D, Goyal L. The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer. Ann Oncol. 2022 Sep 8:S0923-7534(22)04141-2. doi: 10.1016/j.annonc.2022.09.150. PMID: 36089135.

Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 Sep 15;13(1):5345. doi: 10.1038/s41467-022-32701-6. PMID: 36109521; PMCID: PMC9477876.

Li Y, Chyan MK, Hamlin DK, Nguyen H, Corey E, Wilbur DS. Oxidation of p-[125I]Iodobenzoic Acid and p-[211At]Astatobenzoic Acid Derivatives and Evaluation In Vivo. Int J Mol Sci. 2022 Sep 13;23(18):10655. doi: 10.3390/ijms231810655. PMID: 36142567.

Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, Arranz JA, Oudard S, Massard C, Heinzelbecker J, Nordquist LT, Carles J, Kolinsky MP, Augustin M, Gurney H, Tafreshi A, Li XT, Qiu P, Poehlein CH, Schloss C, de Bono JS. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. Eur Urol. 2022 Aug 30:S0302-2838(22)02554-4. doi: 10.1016/j.eururo.2022.08.005. PMID: 36055895.

Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp A. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851. PMID: 35695870; PMCID: PMC9378683.

Snyder LE, Phan DF, Williams KC, Piqueiras E, Connor SE, George S, Kwan L, Villatoro Chavez J, Tandel MD, Frencher SK, Litwin MS, Gore JL, Hartzler AL. Comprehension, utility, and preferences of prostate cancer survivors for visual timelines of patient-reported outcomes co-designed for limited graph literacy: meters and emojis over comics. J Am Med Inform Assoc. 2022 Aug 30:ocac148. doi: 10.1093/jamia/ocac148. PMID: 36040190.

Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 Aug;608(7921):199-208. doi: 10.1038/s41586-022-04975-9. PMID: 35859180.

Khan HM, Cheng HH. Germline genetics of prostate cancer. Prostate. 2022 Aug;82 Suppl 1(Suppl 1):S3-S12. doi: 10.1002/pros.24340. PMID: 35657157; PMCID: PMC9255908.

Cyrta J, Prandi D, Arora A, Hovelson DH, Sboner A, Rodriguez A, Fedrizzi T, Beltran H, Robinson DR, Gopalan A, True L, Nelson PS, Robinson BD, Mosquera JM, Tomlins SA, Shen R, Demichelis F, Rubin MA. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. J Pathol. 2022 Jul;257(3):274-284. doi: 10.1002/path.5887. PMID: 35220606.

Owens L, Gulati R, Etzioni R. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1298-1304. doi: 10.1158/1055-9965.EPI-22-0024. PMID: 35477176; PMCID: PMC9250620.

Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Wagner AA, Sokoll LJ, Sanda MG, Chan DW, Lin DW. Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. J Urol. 2022 Jul 5:101097JU0000000000002852. doi: 10.1097/JU.0000000000002852. PMID: 35830553.

Hammer L, Jiang R, Hearn J, Lashbrook J, Mitchell A, Daignault-Newton S, Dess RT, Jackson WC, Reichert Z, Alumkal JJ, Kaffenberger S, George A, Montgomery J, Salami SS, Morgan TM, Miller D, Wittman D, Hollenbeck B, Mehra R, Davenport MS, Sun Y, Schipper M, Palapattu G, Spratt DE. A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Jul 22:S0360-3016(22)00736-2. doi: 10.1016/j.ijrobp.2022.07.016. PMID: 35878714.

Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. PMID: 35643841.

Storck WK, May AM, Westbrook TC, Duan Z, Morrissey C, Yates JA, Alumkal JJ. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. Front Endocrinol (Lausanne). 2022 Jul 14;13:926585. doi: 10.3389/fendo.2022.926585. PMID: 35909568; PMCID: PMC9329809.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seilerd R, Black PC, Boormans JL, Dall'Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wrighta JL, Lam HM. Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol. 2022 Jul;40(7):352. doi: 10.1016/j.urolonc.2022.05.011. Epub 2022 May 28. Erratum for: Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. PMID: 35641377.

Symonds L, Konnick E, Vakar-Lopez F, Cheng HH, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B. BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. JCO Precis Oncol. 2022 Jul;6:e2200091. doi: 10.1200/PO.22.00091. PMID: 35834759; PMCID: PMC9307304.

Wang X, Jordahl KM, Zhu C, Livingstone J, Rhie SK, Wright JL, Grady WM, Boutros PC, Stanford JL, Dai JY. Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1473-1482. doi: 10.1158/1055-9965.EPI-22-0007. PMID: 35437583; PMCID: PMC9250603.

Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Jun 5:S1558-7673(22)00125-2. doi: 10.1016/j.clgc.2022.06.001. PMID: 35778337.

Basourakos SP, Gulati R, Vince RA Jr, Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. NEJM Evid. 2022 Jun;1(6):10.1056/evidoa2200031. doi: 10.1056/evidoa2200031. PMID: 35721307; PMCID: PMC9202998.

Dong X, Xue H, Mo F, Lin YY, Lin D, Wong NKY, Sun Y, Wilkinson S, Ku AT, Hao J, Ci X, Wu R, Haegert A, Silver R, Taplin ME, Balk SP, Alumkal JJ, Sowalsky AG, Gleave M, Collins C, Wang Y. Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications. Mol Cancer Res. 2022 May 4;20(5):782-793. doi: 10.1158/1541-7786.MCR-21-1037. PMID: 35082166.

Feng Z, Curti BD, Quinn DI, Strother JM, Chen Z, Agnor R, Beer TM, Ryan CW. A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2022 May 5:S1558-7673(22)00094-5. doi: 10.1016/j.clgc.2022.04.018. PMID: 35688679.

Kim YS, Hsieh AC, Lam HM. Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery. Eur Urol Focus. 2022 May;8(3):657-659. doi: 10.1016/j.euf.2022.07.006. PMID: 35915037.

Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, Gu S, Tang Q, Zhang Y, Syamala S, Seo JH, Bell C, O'Connor E, Liu Y, Schaeffer EM, Jeffrey Karnes R, Weinmann S, Davicioni E, Morrissey C, Cejas P, Ellis L, Loda M, Wucherpfennig KW, Pomerantz MM, Spratt DE, Corey E, Freedman ML, Shirley Liu X, Brown M, Long HW, Labbé DP. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun. 2022 May 13;13(1):2559. doi: 10.1038/s41467-022-30257-z. PMID: 35562350; PMCID: PMC9106722.

Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, Corey E, Chandel NS, Catalona WJ, Yang X, Freedman ML, Zhao JC, Yu  J. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer..Nat Genet. 2022 May;54(5):670-683. doi: 10.1038/s41588-022-01045-8. PMID: 35468964 PMCID: PMC9117466

Montgomery B, Wang S, Rettig M, Lee B, Bates J, Pritchard C. Ordering and Interpreting Precision Oncology Studies for Adults With Advanced Solid Tumors: A Primer. Fed Pract. 2022 May;39(Suppl 2):S16-S24. doi: 10.12788/fp.0270. PMID: 35929009; PMCID: PMC9346578.

Lu X, Fong KW, Gritsina G, Wang F, Baca SC, Brea LT, Berchuck JE, Spisak S, Ross J, Morrissey C, Corey E, Chandel NS, Catalona WJ, Yang X, Freedman ML, Zhao JC, Yu J. HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nat Genet. 2022 May;54(5):670-683. doi: 10.1038/s41588-022-01045-8. PMID: 35468964; PMCID: PMC9117466.

Sun D, Guan X, Moran AE, Wu LY, Qian DZ, Schedin P, Dai MS, Danilov AV, Alumkal JJ, Adey AC, Spellman PT, Xia Z. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. 2022 Apr;40(4):527-538. doi: 10.1038/s41587-021-01091-3. PMID: 34764492; PMCID: PMC9010342.

Wei X, Roudier MP, Kwon OJ, Lee JD, Kong K, Dumpit R, True L, Morrissey C, Lin DW, Nelson PS, Xin L. Paracrine Wnt signaling is necessary for prostate epithelial proliferation. Prostate. 2022 Apr;82(5):517-530. doi: 10.1002/pros.24298. PMID: 35014711; PMCID: PMC8866211.

Ouellet V, Erickson A; GAP1 UTMAs Contributing Investigators, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM, Garraway IP, Trock BJ, Taimen P, Saad F, Mirtti T, Knudsen BS, De Marzo AM. The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):715-727. doi: 10.1158/1055-9965.EPI-21-0600. PMID: 35131885.

Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021 Mar 3;12(1):1426. doi: 10.1038/s41467-021-21615-4. PMID: 33658518; PMCID: PMC7930198.

Berchuck JE, Baca SC, McClure HM, Korthauer K, Tsai HK, Nuzzo PV, Kelleher KM, He M, Steinharter JA, Zacharia S, Spisak S, Seo JH, Conteduca V, Elemento O, Auh J, Sigouros M, Corey E, Hirsch MS, Taplin ME, Choueiri TK, Pomerantz MM, Beltran H, Freedman ML. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 1;28(5):928-938. doi: 10.1158/1078-0432.CCR-21-3762. PMID: 34907080.

Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, Kohlmann W, Naumer A, Vagher J, Greenberg SE, Naylor L, Laurino M, Konnick EQ, Shirts BH, AlDubayan SH, Van Allen EM, Nguyen B, Vijai J, Abida W, Carlo MI, Dubard-Gault M, Lee DJ, Maese LD, Mandelker D, Montgomery B, Morris MJ, Nicolosi P, Nussbaum RL, Schwartz LE, Stadler Z, Garber JE, Offit K, Schiffman JD, Nelson PS, Sartor O, Walsh MF, Pritchard CC. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol. 2022 Mar;81(3):243-250. doi: 10.1016/j.eururo.2021.10.036. PMID: 34863587; PMCID: PMC8891030.

Xue C, Corey E, Gujral. Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors. TS.Cancers (Basel). 2022 Mar 29;14(7):1739. doi: 10.3390/cancers14071739.PMID: 35406510 PMCID: PMC8997167

Wang CK, Nelepcu I, Hui D, Oo HZ, Truong S, Zhao S, Tahiry Z, Esfandnia S, Ghaidi F, Adomat H, Dagil R, Gustavsson T, Choudhary S, Salanti A, Sorensen PH, Al Nakouzi N, Daugaard M. Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells. Sci Rep. 2022 Feb 23;12(1):3075. doi: 10.1038/s41598-022-07025-6. PMID: 35197518; PMCID: PMC8866492.

Monga J, Adrianto I, Rogers C, Gadgeel S, Chitale D, Alumkal JJ, Beltran H, Zoubeidi A, Ghosh J. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem. 2022 Feb;298(2):101556. PMID: 34973338; PMCID: PMC8800106.

Wang Z, Hulsurkar M, Zhuo L, Xu J, Yang H, Naderinezhad S, Wang L, Zhang G, Ai N, Li L, Chang JT, Zhang S, Fazli L, Creighton CJ, Bai F, Ittmann MM, Gleave ME, Li W. CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia. 2021 Oct 23;23(11):1147-1165. doi: 10.1016/j.neo.2021.09.005. Epub ahead of print. PMID: 34706306.

Leblanc E, Ban F, Cavga AD, Lawn S, Huang CF, Mohan S, Chang MEK, Flory MR, Ghaidi F, Lingadahalli S, Chen G, Yu IPL, Morin H, Lallous N, Gleave ME, Mohammed H, Young RN, Rennie PS, Lack NA, Cherkasov A. Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. J Med Chem. 2021 Oct 28;64(20):14968-14982. doi: 10.1021/acs.jmedchem.1c00681. Epub 2021 Oct 18. PMID: 34661404.

Martin NA, Tepper JE, Giri VN, Stinchcombe TE, Cheng HH, Javle MM, Konnick EQ. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precis Oncol. 2021 Oct 6;5:PO.21.00027. doi: 10.1200/PO.21.00027. PMID: 34651094; PMCID: PMC8509918.

Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Alaiwi SA, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrisey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 Oct 1;12(1):5775. doi: 10.1038/s41467-021-26042-z. PMID: 34599169; PMCID: PMC8486778.

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021 Oct 1. doi: 10.1111/bju.15603. Epub ahead of print. PMID: 34597472.

Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A, Mikos AG, Nelson PS, Dondossola E, Gujral TS. Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):e2103623118. doi: 10.1073/pnas.2103623118. Epub 2021 Sep 30. PMID: 34593636; PMCID: PMC8501846.

Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2021 Sep 30:jnumed.121.263262. doi: 10.2967/jnumed.121.263262. Epub ahead of print. PMID: 34593595.

Graham LS, Pritchard CC, Schweizer MT. Hypermutation, Mismatch Repair Deficiency and Defining Predictors of Response to Checkpoint Blockade. Clin Cancer Res. 2021 Sep 27:clincanres.3031.2021. doi: 10.1158/1078-0432.CCR-21-3031. Epub ahead of print. PMID: 34580112.

Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Sep 23:e213987. doi: 10.1001/jamaoncol.2021.3987. Epub ahead of print. PMID: 34554200; PMCID: PMC8461554.

Jiao B, Gulati R, Katki HA, Castle PE, Etzioni R. A Quantitative Framework to Study Potential Benefits and Harms of Multi-cancer Early Detection Testing. Cancer Epidemiol Biomarkers Prev. 2021 Sep 20:cebp.0380.2021. doi: 10.1158/1055-9965.EPI-21-0380. Epub ahead of print. PMID: 34548329.

Zimmer BM, Howell ME, Ma L, Enders JR, Lehman D, Corey E, Barycki JJ, Simpson MA. Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer. Oncotarget. 2021 Sep 14;12(19):1886-1902. doi: 10.18632/oncotarget.28059. PMID: 34548906; PMCID: PMC8448517.

Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate. 2021 Sep 13. doi: 10.1002/pros.24236. Epub ahead of print. PMID: 34516663

Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer Prostatic Dis. 2021 Sep 13. doi: 10.1038/s41391-021-00447-9. Epub ahead of print. PMID: 34518652.

 Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911. Epub ahead of print. PMID: 34516660.

Chang E, Apolo AB, Bangs R, Chisolm S, Duddalwar V, Efstathiou JA, Goldberg KB, Hansel DE, Kamat AM, Kluetz PG, Lerner SP, Plimack E, Prowell T, Singh H, Suzman D, Yu EY, Zhang H, Beaver JA, Pazdur R, Weinstock C, Galsky MD. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2021 Sep 10. doi: 10.1038/s41585-021-00505-w. Epub ahead of print. PMID: 34508246

Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, Allen JW, Thompson MA, Tran NL, Moldvay J, Dome B, Salanti A, Al-Nakouzi N, Weiss GJ, Daugaard M. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer. Cancers (Basel). 2021 Sep 6;13(17):4489. doi: 10.3390/cancers13174489. PMID: 34503301; PMCID: PMC8430715.

Smith AB, Lee JR, Lawrence SO, Lavallee DC, Chisolm S, MacLean DB, Louwers RK, Wolff EM, Kessler LG, Follmer KM, Gore JL. Patient and public involvement in the design and conduct of a large, pragmatic observational trial to investigate recurrent, high-risk non-muscle-invasive bladder cancer. Cancer. 2021 Sep 8. doi: 10.1002/cncr.33897. Epub ahead of print. PMID: 34495550.

Goel S, Bhatia V, Kundu S, Biswas T, Carskadon S, Gupta N, Asim M, Morrissey C, Palanisamy N, Ateeq B. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression. Nat Commun. 2021 Sep 7;12(1):5325. doi: 10.1038/s41467-021-25623-2. PMID: 34493733.

Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng FM, Epstein J, Fine SW, Genega EM, Hirsch MS, Humphrey PA, Gordetsky J, Kristiansen G, Kunju LP, Magi-Galluzzi C, Gupta N, Netto GJ, Osunkoya AO, Robinson BD, Trpkov K, True LD, Troncoso P, Varma M, Wheeler T, Williamson SR, Wu A, Zhou M. Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res. 2021 Aug 15;11(8):3990-4001. PMID: 34522463; PMCID: PMC8414383.

Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, Marks LS, Vesprini D, Goldenberg SL, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Helfand BT, Scholtens DM, Witte JS, Catalona WJ. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937. Epub ahead of print. PMID: 34503355.

Gulati R, Carlsson SV, Etzioni R. When to Discuss Prostate Cancer Screening With Average-Risk Men. Am J Prev Med. 2021 Aug;61(2):294-298. doi: 10.1016/j.amepre.2021.02.024. Epub 2021 May 6. PMID: 33966938; PMCID: PMC8319088.

Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, Etzioni R. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value Health. 2021 Aug;24(8):1111-1117. doi: 10.1016/j.jval.2021.02.009. Epub 2021 Apr 22. PMID: 34372976; PMCID: PMC8358184.

D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Aug 9. doi: 10.1007/s00345-021-03793-4. Epub ahead of print. PMID: 34370078

Shee K, Pal SK, Wells JC, Ruiz-Morales JM, Russell K, Dudani S, Choueiri TK, Heng DY, Gore JL, Odisho AY. Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clin Cancer Inform. 2021 Aug;5:912-920. doi: 10.1200/CCI.21.00050. PMID: 34464153.

Etzioni R, Haffner MC, Gulati R. Divining Harm-Benefit Tradeoffs of Magnetic Resonance Imaging-targeted Biopsy. Eur Urol. 2021 Aug 31:S0302-2838(21)01977-1. doi: 10.1016/j.eururo.2021.08.009. Epub ahead of print. PMID: 34479754

Lee JH, Hong J, Zhang Z, de la Peña Avalos B, Proietti CJ, Deamicis AR, Guzmán G P, Lam HM, Garcia J, Roudier MP, Sisk AE, De La Rosa R, Vu K, Yang M, Liao Y, Scheirer J, Pechacek D, Yadav P, Rao MK, Zheng S, Johnson-Pais TL, Leach RJ, Elizalde PV, Dray E, Xu K. Regulation of telomere homeostasis and genomic stability in cancer by N⁶-adenosine methylation (m⁶A). Sci Adv. 2021 Jul 28;7(31):eabg7073. doi: 10.1126/sciadv.abg7073. PMID: 34321211.

Feldman AS, Lokeshwar V, Lin DW. A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urol Oncol. 2021 Jul 24:S1078-1439(21)00269-6. doi: 10.1016/j.urolonc.2021.06.010. Epub ahead of print. PMID: 34315659.

Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, Shariat S, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Adv Anat Pathol. 2021 Jul 1;28(4):179-195. doi: 10.1097/PAP.0000000000000308. PMID: 34128483.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer. Cancer Res. 2021 Jul 26:canres.0307.2021. doi: 10.1158/0008-5472.CAN-21-0307. Epub ahead of print. PMID: 34312180.

Nadauld LD, McDonnell CH 3rd, Beer TM, Liu MC, Klein EA, Hudnut A, Whittington RA, Taylor B, Oxnard GR, Lipson J, Lopatin M, Shaknovich R, Chung KC, Fung ET, Schrag D, Marinac CR. The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers (Basel). 2021 Jul 13;13(14):3501. doi: 10.3390/cancers13143501. PMID: 34298717; PMCID: PMC8304888

Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh K, Gleave ME, Mohammed H, Rennie PS, Lack NA, Cherkasov A. Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. Cancers (Basel). 2021 Jul 12;13(14):3488. doi: 10.3390/cancers13143488. PMID: 34298700; PMCID: PMC8304761.

Dorff TB, O'Neil B, Hoffman KE, Lin DW, Loughlin KR, Dall'Era M. 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol. 2021 Jul 12:S1078-1439(21)00175-7. doi: 10.1016/j.urolonc.2021.04.016. Epub ahead of print. PMID: 34266741.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322. Epub ahead of print. PMID: 34161051.

Kukreja JB, Schroeck FR, Lotan Y, Gore JL, Ullman R, Lipman RR, Murray MBB, Chisolm S; Cystoscopy Discomfort Working Group, Smith AB. Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urol Oncol. 2021 Jun 20:S1078-1439(21)00215-5. doi: 10.1016/j.urolonc.2021.05.009. Epub ahead of print. PMID: 34162499.

Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 Jun 18:clincanres.4968.2020. doi: 10.1158/1078-0432.CCR-20-4968. Epub ahead of print. PMID: 34145028.

Finelli A, Beer TM, Chowdhury S, Evans CP, Fizazi K, Higano CS, Kim J, Martin L, Saad F, Saarela O. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. JAMA Netw Open. 2021 Jun 1;4(6):e2112426. doi: 10.1001/jamanetworkopen.2021.12426. PMID: 34129025; PMCID: PMC8207237.

Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. Erratum for: Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. PMID: 34128479; PMCID: PMC8203444.

Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. JAMA Oncol. 2021 Jun 4. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print. PMID: 34086042.

Annala M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, Beja K, Sipola J, Warner EW, Herberts C, Wong A, Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW. Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition. Clin Cancer Res. 2021 Jun 3:clincanres.CCR-21-1625-E.2021. doi: 10.1158/1078-0432.CCR-21-1625. Epub ahead of print.

Wenmaekers S, Viergever BJ, Kumar G, Kranenburg O, Black PC, Daugaard M, Meijer RP. A Potential Role for HUWE1 in Modulating Cisplatin Sensitivity. Cells. 2021 May 20;10(5):1262. doi: 10.3390/cells10051262. PMID: 34065298; PMCID: PMC816063434083234.

Sampurno F, Cally J, Opie JL, Kannan A, Millar JL, Finelli A, Vickers AJ, Moore CM, Kowalski C, Foster C, Barocas DA, Galvin D, Van Basten JP, Gore JL, Ferencz J, Lawson KA, Ghani KR, Kwan L, Saarela O, Connor SE, Dieng S, Linsell S, Soeterik TF, Villanti P, Litwin MS, Evans SM. Establishing a global quality of care benchmark report. Health Informatics J. 2021 Apr-Jun;27(2):14604582211015704. doi: 10.1177/14604582211015704. PMID: 34082597.

Do OA, Ferris LA, Holt SK, Ramos JD, Harshman LC, Plimack ER, Crabb SJ, Pal SK, De Giorgi U, Ladoire S, Baniel J, Necchi A, Vaishampayan UN, Bamias A, Bellmunt J, Srinivas S, Dorff TB, Galsky MD, Yu EY. Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. Clin Genitourin Cancer. 2021 Apr;19(2):125-134. doi: 10.1016/j.clgc.2020.10.006. Epub 2020 Nov 12. PMID: 33309564.

Deb S, Chin MY, Pham S, Adomat H, Hurtado-Coll A, Gleave ME, Tomlinson Guns ES. Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue. Int J Mol Sci. 2021 Jan 6;22(2):487. doi: 10.3390/ijms22020487. PMID: 33418978; PMCID: PMC7825320.

Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. PMID: 33328650; PMCID: PMC7969494.

Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Erratum in: Oncogene. 2021 Jun;40(22):3914-3916. PMID: 32989253; PMCID: PMC7655549.

Nyame YA, Gulati R, Heijnsdijk EAM, Tsodikov A, Mariotto AB, Gore JL, Etzioni R. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. J Natl Cancer Inst. 2021 May 8:djab072. doi: 10.1093/jnci/djab072. Epub ahead of print. PMID: 33963850.

Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23. PMID: 33755225; PMCID: PMC8044035.

Ma T, Bai S, Qi Y, Zhan Y, Ungerleider N, Zhang DY, Neklesa T, Corey E, Dehm SM, Zhang K, Flemington EK, Dong Y. Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Cancer Lett. 2021 Apr 28;504:37-48. doi: 10.1016/j.canlet.2020.12.037. Epub 2021 Feb 6. PMID: 33556543; PMCID: PMC7940584.

Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021 Apr 22;6(8):e146827. doi: 10.1172/jci.insight.146827. PMID: 33724955; PMCID: PMC8119192.

Zhang X, Huang Z, Wang J, Ma Z, Yang J, Corey E, Evans CP, Yu AM, Chen HW. Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling. Cancers (Basel). 2021 Apr 1;13(7):1672. doi: 10.3390/cancers13071672. PMID: 33916325; PMCID: PMC8036795.

Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7. PMID: 33785741; PMCID: PMC8010057. 

Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, Gulati R, Plymate SR, Zhou Z, Birditt B, Meredith R, Geiss G, Hoang M, Beechem J, Nelson PS. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021 Mar 3;12(1):1426. doi: 10.1038/s41467-021-21615-4. PMID: 33658518; PMCID: PMC7930198.

McGuire JJ, Frieling JS, Lo CH, Li T, Muhammad A, Lawrence HR, Lawrence NJ, Cook LM, Lynch CC. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nat Commun. 2021 Feb 1;12(1):723. doi: 10.1038/s41467-021-20962-6. PMID: 33526787; PMCID: PMC7851397.

DeLucia DC, Cardillo TM, Ang L, Labrecque MP, Zhang A, Hopkins JE, De Sarkar N, Coleman I, da Costa RMG, Corey E, True LD, Haffner MC, Schweizer MT, Morrissey C, Nelson PS, Lee JK. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. Epub 2020 Nov 16. PMID: 33199493; PMCID: PMC7854497.

Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021 Feb;18(2):79-92. doi: 10.1038/s41585-020-00400-w. Epub 2020 Dec 16. PMID: 33328650; PMCID: PMC7969494.

Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, Corey E, Paulmurugan R, Stoyanova T. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer Res. 2021 Mar 15;81(6):1583-1594. doi: 10.1158/0008-5472.CAN-20-3477. Epub 2021 Jan 22. PMID: 33483372; PMCID: PMC7969452.

Quaglia F, Krishn SR, Wang Y, Goodrich DW, McCue P, Kossenkov AV, Mandigo AC, Knudsen KE, Weinreb PH, Corey E, Kelly WK, Languino LR. Differential expression of αVβ3 and αVβ6 integrins in prostate cancer progression. PLoS One. 2021 Jan 22;16(1):e0244985. doi: 10.1371/journal.pone.0244985. PMID: 33481853; PMCID: PMC7822502.

Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Lin DW, Corey E, Nelson PS, Morrissey C. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. PLoS One. 2021 Jan 20;16(1):e0245602. doi: 10.1371/journal.pone.0245602. PMID: 33471819; PMCID: PMC7817027.

Sokolova AO, Cheng HH. Genetic Testing in Prostate Cancer. Curr Oncol Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11912-020-0863-6. PMID: 31974718.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. Eur Urol. 2020 Feb;77(2):144-155. doi: 10.1016/j.eururo.2019.05.042. Epub 2019 Jun 19. PMID: 31227306; PMCID: PMC6920609.

Barnard M, Mostaghel EA, Auchus RJ, Storbeck KH. The role of adrenal derived androgens in castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2020 Mar;197:105506. doi: 10.1016/j.jsbmb.2019.105506. Epub 2019 Oct 28. PMID: 31672619; PMCID: PMC7883395.

Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020 Mar;77(3):333-341. doi: 10.1016/j.eururo.2019.09.036. Epub 2019 Oct 20. PMID: 31640893; PMCID: PMC7365609.

Schweizer MT, Yu EY. "Matching" the "Mismatch" Repair-Deficient Prostate Cancer with Immunotherapy. Clin Cancer Res. 2020 Mar 1;26(5):981-983. doi: 10.1158/1078-0432.CCR-19-3780. Epub 2020 Jan 3. PMID: 31900277; PMCID: PMC7123990.

Dai JY, Wang X, Wang B, Sun W, Jordahl KM, Kolb S, Nyame YA, Wright JL, Ostrander EA, Feng Z, Stanford JL. DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. PLoS Genet. 2020 Mar 30;16(3):e1008667. doi: 10.1371/journal.pgen.1008667. PMID: 32226005; PMCID: PMC7145271.

Nayak JG, Scalzo N, Chu A, Shiff B, Kearns JT, Dy GW, Macleod LC, Mossanen M, Ellis WJ, Lin DW, Wright JL, True LD, Gore JL. The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):144-150. doi: 10.1038/s41391-019-0169-7. Epub 2019 Aug 28. PMID: 31462701.

Corella AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, Kaipainen A, Nguyen HM, Sondheim D, Brown LG, True LD, Lee JK, MacPherson D, Nghiem P, Gulati R, Morrissey C, Corey E, Nelson PS. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. Clin Cancer Res. 2020 Apr 1;26(7):1667-1677. doi: 10.1158/1078-0432.CCR-19-0775. Epub 2019 Dec 5. PMID: 31806643; PMCID: PMC7124974.

Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precis Oncol. 2020;4:382-392. doi: 10.1200/po.19.00383. Epub 2020 Apr 21. PMID: 32671317; PMCID: PMC7363399.

Weyer-Czernilofsky U, Hofmann MH, Friedbichler K, Baumgartinger R, Adam PJ, Solca F, Kraut N, Nguyen HM, Corey E, Liu G, Sprenger CC, Plymate SR, Bogenrieder T. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. doi: 10.1158/1535-7163.MCT-19-0378. Epub 2020 Feb 13. PMID: 32054790.

Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, Maher CA, Feng FY, de Bono JS, Dehm SM. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clin Cancer Res. 2020 Apr 15;26(8):1965-1976. doi: 10.1158/1078-0432.CCR-19-3023. Epub 2020 Jan 13. PMID: 31932493; PMCID: PMC7165042.

Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Rep. 2020 May 26;31(8):107669. doi: 10.1016/j.celrep.2020.107669. PMID: 32460015; PMCID: PMC7453577.

Qu X, Yeung C, Coleman I, Nelson PS, Fang M. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by QIAGEN. Cancer Genet. 2020 May;243:11-18. doi: 10.1016/j.cancergen.2020.02.007. Epub 2020 Mar 7. PMID: 32197218.

Dines JN, Shirts BH, Slavin TP, Walsh T, King MC, Fowler DM, Pritchard CC. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots". Genet Med. 2020 May;22(5):825-830. doi: 10.1038/s41436-019-0740-6. Epub 2020 Jan 8. PMID: 31911673; PMCID: PMC7200594.

Lin DW, Zheng Y, McKenney JK, Brown MD, Lu R, Crager M, Boyer H, Tretiakova M, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Kolb S, Liss M, Morgan TM, Thompson IM, Wagner AA, Tsiatis A, Pingitore A, Nelson PS, Newcomb LF. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. J Clin Oncol. 2020 May 10;38(14):1549-1557. doi: 10.1200/JCO.19.02267. Epub 2020 Mar 4. PMID: 32130059; PMCID: PMC7213589.

Brady L, Gil da Costa RM, Coleman IM, Matson CK, Risk MC, Coleman RT, Nelson PS. A comparison of prostate cancer cell transcriptomes in 2D monoculture vs 3D xenografts identify consistent gene expression alterations associated with tumor microenvironments. Prostate. 2020 May;80(6):491-499. doi: 10.1002/pros.23963. Epub 2020 Feb 18. PMID: 32068909; PMCID: PMC7148119.

Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12315-12323. doi: 10.1073/pnas.1922207117. Epub 2020 May 18. PMID: 32424106; PMCID: PMC7275746.

Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, Alumkal JJ. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. Neoplasia. 2020 Jun;22(6):253-262. doi: 10.1016/j.neo.2020.04.002. Epub 2020 May 11. PMID: 32403054; PMCID: PMC7218227.

Sokolova AO, Yu EY, Cheng HH. Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. Clin Cancer Res. 2020 Jun 1;26(11):2439-2440. doi: 10.1158/1078-0432.CCR-20-0707. Epub 2020 Mar 31. PMID: 32234758; PMCID: PMC7269828.

Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, Gusev A, Korthauer KD, Severson TM, Ha G, Viswanathan SR, Seo JH, Nguyen HM, Zhang B, Pasaniuc B, Giambartolomei C, Alaiwi SA, Bell CA, O'Connor EP, Chabot MS, Stillman DR, Lis R, Font-Tello A, Li L, Cejas P, Bergman AM, Sanders J, van der Poel HG, Gayther SA, Lawrenson K, Fonseca MAS, Reddy J, Corona RI, Martovetsky G, Egan B, Choueiri T, Ellis L, Garraway IP, Lee GM, Corey E, Long HW, Zwart W, Freedman ML. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 Aug;52(8):790-799. doi: 10.1038/s41588-020-0664-8. Epub 2020 Jul 20. PMID: 32690948.

VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM. Targeting RET Kinase in Neuroendocrine Prostate Cancer. Mol Cancer Res. 2020 Aug;18(8):1176-1188. doi: 10.1158/1541-7786.MCR-19-1245. Epub 2020 May 27. PMID: 32461304; PMCID: PMC7415621.

Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Sep 1;26(17):4616-4624. doi: 10.1158/1078-0432.CCR-19-2303. Epub 2020 Jul 29. PMID: 32727885; PMCID: PMC7484240.

Kang N, Eccleston M, Clermont PL, Latarani M, Male DK, Wang Y, Crea F. EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics. 2020 Aug;12(16):1457-1476. doi: 10.2217/epi-2020-0186. Epub 2020 Sep 17. PMID: 32938196; PMCID: PMC7607396.

Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686. PMID: 32997692; PMCID: PMC7526881.

Wang X, Grasso CS, Jordahl KM, Kolb S, Nyame YA, Wright JL, Ostrander EA, Troyer DA, Lance R, Feng Z, Dai JY, Stanford JL. Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):494-506. doi: 10.1038/s41391-020-0212-8. Epub 2020 Feb 18. PMID: 32071439; PMCID: PMC7725282.

Nyame YA, Gulati R, Tsodikov A, Gore JL, Etzioni R. Prostate-Specific Antigen Screening and Recent Increases in Advanced Prostate Cancer. JNCI Cancer Spectr. 2020 Oct 26;5(1):pkaa098. doi: 10.1093/jncics/pkaa098. PMID: 33442662; PMCID: PMC7791607.

Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5338-5347. doi: 10.1158/1078-0432.CCR-20-1707. Epub 2020 Jul 21. PMID: 32694156; PMCID: PMC7572827.

Cackowski FC, Kumar-Sinha C, Mehra R, Wu YM, Robinson DR, Alumkal JJ, Chinnaiyan AM. Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. JCO Precis Oncol. 2020 Nov 16;4:PO.20.00309. doi: 10.1200/PO.20.00309. PMID: 33283137; PMCID: PMC7713564.

Potluri HK, Ng TL, Newton MA, Zhang J, Maher CA, Nelson PS, McNeel DG. Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. J Immunother Cancer. 2020 Dec;8(2):e001510. doi: 10.1136/jitc-2020-001510. PMID: 33335027; PMCID: PMC7745697.

Xie W, Glaser AK, Vakar-Lopez F, Wright JL, Reder NP, Liu JTC, True LD. Diagnosing 12 prostate needle cores within an hour of biopsy via open-top light-sheet microscopy. J Biomed Opt. 2020 Dec;25(12):126502. doi: 10.1117/1.JBO.25.12.126502. PMID: 33325186; PMCID: PMC7744172.

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26. PMID: 30334814; PMCID: PMC6307949.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.  Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21. Erratum in: Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18893. PMID: 30578319; PMCID: PMC6329966.

Song B, Park SH, Zhao JC, Fong KW, Li S, Lee Y, Yang YA, Sridhar S, Lu X, Abdulkadir SA, Vessella RL, Morrissey C, Kuzel TM, Catalona W, Yang X, Yu J. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression. J Clin Invest. 2019 Feb 1;129(2):569-582. doi: 10.1172/JCI122367. Epub 2018 Dec 18. PMID: 30511964; PMCID: PMC6355239.

Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019 Feb;21(2):238-250. doi: 10.1038/s41556-018-0267-0. Epub 2019 Jan 21. PMID: 30664790; PMCID: PMC6948102.

Dehm SM, Montgomery B, Plymate SR. AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome? Clin Cancer Res. 2019 Mar 15;25(6):1696-1698. doi: 10.1158/1078-0432.CCR-18-3727. Epub 2018 Dec 27. PMID: 30591516.

Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14. PMID: 30773341; PMCID: PMC7246081.

Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 Jun;17(6):1235-1240. doi: 10.1158/1541-7786.MCR-18-1101. Epub 2019 Mar 27. PMID: 30918106; PMCID: PMC6548614.

Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, Coleman R, Higano CS, Yu EY, Cheng HH, Mostaghel EA, Montgomery B, Schweizer MT, Hsieh AC, Lin DW, Corey E, Nelson PS, Morrissey C. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019 Jul 30;129(10):4492-4505. doi: 10.1172/JCI128212. PMID: 31361600; PMCID: PMC6763249.

Yang J, Broman MM, Cooper PO, Lanman NA, Strand DW, Morrissey C, Ratliff TL. Distinct expression patterns of SULT2B1b in human prostate epithelium. Prostate. 2019 Aug;79(11):1256-1266. doi: 10.1002/pros.23829. Epub 2019 Jun 18. PMID: 31212370; PMCID: PMC7064034.

Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18. PMID: 31171481; PMCID: PMC6662206.

Kaipainen A, Zhang A, Gil da Costa RM, Lucas J, Marck B, Matsumoto AM, Morrissey C, True LD, Mostaghel EA, Nelson PS. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion. Prostate. 2019 Sep;79(13):1530-1542. doi: 10.1002/pros.23874. Epub 2019 Aug 2. PMID: 31376206; PMCID: PMC6783279.

Cook LM, Frieling JS, Nerlakanti N, McGuire JJ, Stewart PA, Burger KL, Cleveland JL, Lynch CC. Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis. Oncogene. 2019 Oct;38(44):6959-6969. doi: 10.1038/s41388-019-0913-4. Epub 2019 Aug 13. PMID: 31409900; PMCID: PMC7771554.

Nyquist MD, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers DA, Lucas JM, Paddison PJ, Plymate SR, Nelson PS, Mostaghel EA. Molecular determinants of response to high-dose androgen therapy in prostate cancer. JCI Insight. 2019 Oct 3;4(19):e129715. doi: 10.1172/jci.insight.129715. PMID: 31503550; PMCID: PMC6795499.

Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene. 2019 Nov;38(45):7060-7072. doi: 10.1038/s41388-019-0947-7. Epub 2019 Aug 13. PMID: 31409897; PMCID: PMC6842090.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Nov;76(5):562-571. doi: 10.1016/j.eururo.2019.03.020. Epub 2019 Mar 28. PMID: 30928160; PMCID: PMC6764911.Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, Corey E, Fazli L, Ledet E, Zhang R, Silberstein JL, Zhang W, Zhang K, Sartor O, Dong X, Flemington EK, Dong Y. Circular RNAs add diversity to  androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0947-7. [Epub ahead of print] PubMed PMID: 31409897.

Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate. 2019 Oct;79(14):1589-1596. doi: 10.1002/pros.23882. Epub 2019 Aug 2. PubMed PMID: 31376183; PubMed Central PMCID: PMC6715522.

Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen  L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Sci Transl Med. 2019 Jul 31;11(503). pii: eaaw4993. doi: 10.1126/scitranslmed.aaw4993. PubMed PMID: 31366581; PubMed Central PMCID: PMC6746573.

Glaser AK, Reder NP, Chen Y, Yin C, Wei L, Kang S, Barner LA, Xie W, McCarty EF, Mao C, Halpern AR, Stoltzfus CR, Daniels JS, Gerner MY, Nicovich PR, Vaughan  JC, True LD, Liu JTC. Multi-immersion open-top light-sheet microscope for high-throughput imaging of cleared tissues. Nat Commun. 2019 Jul 4;10(1):2781. doi: 10.1038/s41467-019-10534-0. PubMed PMID: 31273194; PubMed Central PMCID: PMC6609674.

Lam HM, Nguyen HM, Labrecque MP, Brown LG, Coleman IM, Gulati R, Lakely B, Sondheim D, Chatterjee P, Marck BT, Matsumoto AM, Mostaghel EA, Schweizer MT, Nelson PS, Corey E. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. Eur Urol. 2019 Jun 19. pii: S0302-2838(19)30449-X. doi: 10.1016/j.eururo.2019.05.042. [Epub ahead of print] PubMed PMID: 31227306.

Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer LJ, Campisi J, Coppé JP. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019 Jun 11;5. pii: 124716. doi: 10.1172/jci.insight.124716. PubMed PMID: 31184599; PubMed Central PMCID: PMC6675550.

Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18. PubMed PMID: 31171481; PubMed Central PMCID: PMC6662206.

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY,  Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence  of DNA Repair Gene Mutations. JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00327. Epub 2019 Apr 18. PubMed PMID: 31123724; PubMed Central PMCID: PMC6528668.

Gordon JA, Noble JW, Midha A, Derakhshan F, Wang G, Adomat HH, Tomlinson Guns ES, Lin YY, Ren S, Collins CC, Nelson PS, Morrissey C, Wasan KM, Cox ME. Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. Cancer Res. 2019 Jul 1;79(13):3320-3331. doi: 10.1158/0008-5472.CAN-18-2529. Epub 2019 May 7. PubMed PMID: 31064850; PubMed Central PMCID: PMC6606386.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW,  Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6. PubMed PMID: 31061129; PubMed Central PMCID: PMC6561293.

Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM, Alumkal JJ. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. 2019 Jul;38(28):5658-5669. doi: 10.1038/s41388-019-0815-5. Epub 2019 Apr 17. PubMed PMID: 30996246; PubMed Central PMCID: PMC6677126.

Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019 May 15;79(10):2580-2592. doi: 10.1158/0008-5472.CAN-18-2812. Epub 2019 Apr 5. PubMed PMID: 30952632; PubMed Central PMCID: PMC6522281.

Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ; West Coast Prostate Cancer Dream Team. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206-4. doi: 10.1016/j.eururo.2019.03.020. [Epub ahead of print] PubMed PMID: 30928160; PubMed Central PMCID: PMC6764911.

Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EA. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019 Mar 19. doi: 10.1038/s41391-019-0141-6. [Epub ahead of print] PubMed PMID: 30890759; PubMed Central PMCID: PMC6752995.

Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13. PubMed PMID: 30865311; PubMed Central PMCID: PMC6589085.

Coleman DJ, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, Chiotti KE, Heiser LM, Alumkal JJ. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Sci Rep. 2019 Mar 7;9(1):3823. doi: 10.1038/s41598-019-40518-5. PubMed PMID: 30846826; PubMed Central PMCID: PMC6405739.

Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21. PubMed PMID: 30797618; PubMed Central PMCID: PMC6703974.

Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Ryan CJ, Schaeffer EM,  Stadler WM, Taplin ME, Kauff ND, Vinson J, Antonarakis ES, Cheng HH. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16. PubMed PMID: 30761386; PubMed Central PMCID: PMC6370313.

Hui DHF, Tam KJ, Jiao IZF, Ong CJ. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers. Int J Mol Sci. 2019 Feb 12;20(3). pii: E774. doi:10.3390/ijms20030774. Review. PubMed PMID: 30759745; PubMed Central PMCID: PMC6386986.

Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, Robinson DR, Nesvizhskii AI, Chinnaiyan AM. The Landscape of Circular RNA in Cancer. Cell. 2019 Feb 7;176(4):869-881.e13. doi: 10.1016/j.cell.2018.12.021. PubMed PMID: 30735636; PubMed Central PMCID: PMC6601354.

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 1;38(5). pii: e99599. doi: 10.15252/embj.201899599. Epub 2019 Feb 5. PubMed PMID: 30723117; PubMed Central PMCID: PMC6396169.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U  S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21. PubMed PMID: 30578319; PubMed Central PMCID: PMC6329966.

Lee CCW, Munuganti RSN, Peacock JW, Dalal K, Jiao IZF, Shepherd A, Liu L, Tam KJ, Sedgwick CG, Bhasin S, Lee KCK, Gooding L, Vanderkruk B, Tombe T, Gong Y, Gleave ME, Cherkasov A, Ong CJ. Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc. 2018 Oct 11;2(12):1381-1394. doi: 10.1210/js.2018-00170. eCollection 2018 Dec 1. PubMed PMID: 30534631; PubMed Central PMCID: PMC6280316.

Mostaghel EA. Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res. 2019 Feb 15;25(4):1139-1141. doi: 10.1158/1078-0432.CCR-18-3410. Epub 2018 Dec 10. PubMed PMID: 30530817; PubMed Central PMCID: PMC6377826.

Dai JY, Wang B, Wang X, Cheng A, Kolb S, Stanford JL, Wright JL. Vigorous Physical Activity Is Associated with Lower Risk of Metastatic-Lethal Progression in Prostate Cancer and Hypomethylation in the CRACR2A Gene. Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):258-264. doi: 10.1158/1055-9965.EPI-18-0622. Epub 2018 Nov 21. PubMed PMID: 30464020; PubMed Central PMCID: PMC6363836.

Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SR. Androgen  receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26. PubMed PMID: 30334814; PubMed Central PMCID: PMC6307949.

Bello T, Gujral TS. KInhibition: A Kinase Inhibitor Selection Portal. iScience. 2018 Oct 26;8:49-53. doi: 10.1016/j.isci.2018.09.009. Epub 2018 Sep 18. PubMed PMID: 30273912; PubMed Central PMCID: PMC6170255.

Zhu Y, Podolak J, Zhao R, Shukla AK, Moore RJ, Thomas GV, Kelly RT. Proteome  Profiling of 1 to 5 Spiked Circulating Tumor Cells Isolated from Whole Blood Using Immunodensity Enrichment, Laser Capture Microdissection, Nanodroplet Sample Processing, and Ultrasensitive nanoLC-MS. Anal Chem. 2018 Oct 16;90(20):11756-11759. doi: 10.1021/acs.analchem.8b03268. Epub 2018 Oct 5. PubMed PMID: 30269481; PubMed Central PMCID: PMC6686195.

Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SP. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 Nov 15;78(22):6354-6362. doi: 10.1158/0008-5472.CAN-18-0687. Epub 2018 Sep 21. PubMed PMID: 30242112; PubMed Central PMCID: PMC6239953.

Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Jan 1;25(1):426-439. doi: 10.1158/1078-0432.CCR-18-1431. Epub 2018 Sep 4. PubMed PMID: 30181386; PubMed Central PMCID: PMC6320302.

Frank S, Nelson P, Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Res. 2018 Aug 2;7. pii: F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018. Review. PubMed PMID: 30135717; PubMed Central PMCID: PMC6073096.

Ganaie AA, Beigh FH, Astone M, Ferrari MG, Maqbool R, Umbreen S, Parray AS, Siddique HR, Hussain T, Murugan P, Morrissey C, Koochekpour S, Deng Y, Konety BR, Hoeppner LH, Saleem M. BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in  Race-specific Models. Clin Cancer Res. 2018 Dec 15;24(24):6421-6432. doi: 10.1158/1078-0432.CCR-18-1394. Epub 2018 Aug 7. PubMed PMID: 30087142; PubMed Central PMCID: PMC6295260.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J,  Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889. PubMed PMID: 30033370; PubMed Central PMCID: PMC6425931.

Lim DM, Gulati R, Aleshin-Guendel S, Gawne A, Wingate JT, Cheng HH, Etzioni R, Yu EY. Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate. 2018 Jul 10. doi: 10.1002/pros.23666. [Epub ahead of print] PubMed PMID: 29987912; PubMed Central PMCID: PMC6328347.

Zhao S, Leonardson A, Geybels MS, McDaniel AS, Yu M, Kolb S, Zong H, Carter K, Siddiqui J, Cheng A, Wright JL, Pritchard CC, Lance R, Troyer D, Fan JB, Ostrander EA, Dai JY, Tomlins SA, Feng Z, Stanford JL. A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate. 2018 Jun 28. doi: 10.1002/pros.23667. [Epub ahead of print] PubMed PMID: 29956356; PubMed Central PMCID: PMC6120526.

Plymate SR, Sharp A, de Bono JS. Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol. 2018 Sep 1;4(9):1187-1188. doi: 10.1001/jamaoncol.2018.1615. PubMed PMID: 29955776.

Barnard M, Quanson JL, Mostaghel E, Pretorius E, Snoep JL, Storbeck KH. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J  Steroid Biochem Mol Biol. 2018 Oct;183:192-201. doi: 10.1016/j.jsbmb.2018.06.013. Epub 2018 Jun 21. PubMed PMID: 29936123; PubMed Central PMCID: PMC6283102.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. PubMed PMID: 29921690; PubMed Central PMCID: PMC6095796.

Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, Zhang Z, Gydush GJ, Rotem D; PCF/SU2C International Prostate Cancer Dream Team, Love JC, Getz G, Gabriel S, Zhang CZ, Dehm SM, Nelson PS, Van Allen EM, Choudhury AD, Adalsteinsson VA, Beroukhim R, Taplin ME, Meyerson M. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 Jul 12;174(2):433-447.e19. doi: 10.1016/j.cell.2018.05.036. Epub 2018 Jun 18. PubMed PMID: 29909985; PubMed Central PMCID: PMC6046279.

Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A; PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM. Inactivation of CDK12 Delineates a Distinct Immunogenic Class  of Advanced Prostate Cancer. Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. PubMed PMID: 29906450; PubMed Central PMCID: PMC6084431.

Lam HM, Corey E. Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol. 2018 May 22;8:167. doi: 10.3389/fonc.2018.00167. eCollection 2018. PubMed PMID: 29872642; PubMed Central PMCID: PMC5972313.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. Erratum in: PLoS One. 2018 Aug 15;13(8):e0202709. PubMed PMID: 29856824; PubMed Central PMCID: PMC5983471.

Lam HM, Nguyen HM, Corey E. Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods Mol Biol. 2018;1786:1-27. doi: 10.1007/978-1-4939-7845-8_1. PubMed PMID: 29786784; PubMed Central PMCID: PMC6743725.

Das L, Gard JMC, Prekeris R, Nagle RB, Morrissey C, Knudsen BS, Miranti CK, Cress AE. Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer. Mol Cancer Res. 2018 Aug;16(8):1319-1331. doi: 10.1158/1541-7786.MCR-17-0589. Epub 2018 May 14. PubMed PMID: 29759989; PubMed Central PMCID: PMC6369592.

Glaser AK, Reder NP, Chen Y, McCarty EF, Yin C, Wei L, Wang Y, True LD, Liu JTC. Light-sheet microscopy for slide-free non-destructive pathology of large clinical specimens. Nat Biomed Eng. 2017 Jul;1(7). pii: 0084. doi: 10.1038/s41551-017-0084. Epub 2017 Jun 26. PubMed PMID: 29750130; PubMed Central PMCID: PMC5940348.

Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10. PubMed PMID: 29748182; PubMed Central PMCID: PMC6125202.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team, Schultz N, Van Allen EM. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. Erratum in: Nat Genet. 2019 Jul;51(7):1194. PubMed PMID: 29610475; PubMed Central PMCID: PMC6107367.

Sehrawat A, Gao L, Wang Y, Bankhead A 3rd, McWeeney SK, King CJ, Schwartzman  J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, Berry DL, Haque R, Van Den Eeden SK, Sharma S, Bearss J, Beer TM, Thomas GV, Heiser LM, Alumkal JJ. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188. doi: 10.1073/pnas.1719168115. Epub 2018 Mar 26. PubMed PMID: 29581250; PubMed Central PMCID: PMC5939079.

Cheng HH. The resounding effect of DNA repair deficiency in prostate cancer.  Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17. Review. PubMed PMID: 29555412; PubMed Central PMCID: PMC6746340.

Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. Regulation of inside-out β1-integrin activation by CDCP1. Oncogene. 2018 May;37(21):2817-2836. doi: 10.1038/s41388-018-0142-2. Epub 2018 Mar 7. PubMed PMID: 29511352.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8. PubMed PMID: 29429804; PubMed Central PMCID: PMC6745088.

Uo T, Plymate SR, Sprenger CC. The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets. 2018 Mar;22(3):201-216. doi: 10.1080/14728222.2018.1439016. Epub 2018 Feb 15. Review. PubMed PMID: 29417861.

Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui AL, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med. 2018 Feb;10(2):219-238. doi: 10.15252/emmm.201707689. PubMed PMID: 29348142; PubMed Central PMCID: PMC5801490.

Chalfin HJ, Glavaris SA, Malihi PD, Sperger JM, Gorin MA, Lu C, Goodwin CR, Chen Y, Caruso EA, Dumpit R, Kuhn P, Lang JM, Nelson PS, Luo J, Pienta KJ. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. J Urol. 2018 Jun;199(6):1494-1501. doi: 10.1016/j.juro.2018.01.033. Epub 2018 Jan 12. PubMed PMID: 29339080; PubMed Central PMCID: PMC5964005.

FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):228-237. doi: 10.1038/s41391-017-0029-2. Epub 2018 Jan 3. PubMed PMID: 29298992; PubMed Central PMCID: PMC6026113.

Schenk JM, Song X, Morrissey C, Vessella RL, Lin DW, Neuhouser ML. Plasma Fatty Acids as Surrogate for Prostate Levels. Nutr Cancer. 2018 Jan;70(1):45-50. doi: 10.1080/01635581.2018.1412479. Epub 2017 Dec 21. PubMed PMID: 29267025; PubMed Central PMCID: PMC6188702.

Mohammad OS, Nyquist MD, Schweizer MT, Balk SP, Corey E, Plymate S, Nelson PS, Mostaghel EA. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers (Basel). 2017 Dec 6;9(12). pii: E166. doi: 10.3390/cancers9120166. Review. PubMed PMID: 29210989; PubMed Central PMCID: PMC5742814.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28. PubMed PMID: 29181514; PubMed Central PMCID: PMC5752581.

Geybels MS, Fang M, Wright JL, Qu X, Bibikova M, Klotzle B, Fan JB, Feng Z, Ostrander EA, Nelson PS, Stanford JL. PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget. 2017 Sep 15;8(48):84338-84348. doi: 10.18632/oncotarget.20940. eCollection 2017 Oct 13. PubMed PMID: 29137428; PubMed Central PMCID: PMC5663600.

Schweizer MT, Hancock ML, Getzenberg RH, Yu EY. Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl. 2018 Jul-Aug;20(4):405-406. doi: 10.4103/aja.aja_38_17. PubMed PMID: 29111538; PubMed Central PMCID: PMC6038162.

Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM Jr, Tewari M, Yu EY. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate. 2018 Feb;78(2):121-127. doi: 10.1002/pros.23452. Epub 2017 Nov 6. PubMed PMID: 29105802; PubMed Central PMCID: PMC5728359.

Pan H, Jansson KH, Beshiri ML, Yin J, Fang L, Agarwal S, Nguyen H, Corey E, Zhang Y, Liu J, Fan H, Lin H, Kelly K. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget. 2017 Aug 24;8(44):77181-77194. doi: 10.18632/oncotarget.20424. eCollection 2017 Sep 29. PubMed PMID: 29100379; PubMed Central PMCID: PMC5652772.

Arang N, Kain HS, Glennon EK, Bello T, Dudgeon DR, Walter ENF, Gujral TS, Kaushansky A. Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nat Commun. 2017 Nov 1;8(1):1232. doi: 10.1038/s41467-017-01345-2. PubMed PMID: 29089541; PubMed Central PMCID: PMC5663700.

Yan Q, Bantis LE, Stanford JL, Feng Z. Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med. 2018 Feb 20;37(4):627-642. doi: 10.1002/sim.7535. Epub 2017 Oct 30. PubMed PMID: 29082535; PubMed Central PMCID: PMC6469690.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003. PubMed PMID: 29017058; PubMed Central PMCID: PMC5750052.

Tam KJ, Hui DHF, Lee WW, Dong M, Tombe T, Jiao IZF, Khosravi S, Takeuchi A, Peacock JW, Ivanova L, Moskalev I, Gleave ME, Buttyan R, Cox ME, Ong CJ. Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells. Sci Rep. 2017 Sep 13;7(1):11501. doi: 10.1038/s41598-017-11914-6. PubMed PMID: 28904399; PubMed Central PMCID: PMC5597577.

Zhu Y, Sharp A, Anderson CM, Silberstein JL, Taylor M, Lu C, Zhao P, De Marzo AM, Antonarakis ES, Wang M, Wu X, Luo Y, Su N, Nava Rodrigues D, Figueiredo I, Welti J, Park E, Ma XJ, Coleman I, Morrissey C, Plymate SR, Nelson PS, de Bono JS, Luo J. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 May;73(5):727-735. doi: 10.1016/j.eururo.2017.08.009. Epub 2017 Sep 1. PubMed PMID: 28866255; PubMed Central PMCID: PMC6538073.

Uo T, Plymate SR, Sprenger CC. Allosteric alterations in the androgen receptor and activity in prostate cancer. Endocr Relat Cancer. 2017 Sep;24(9):R335-R348. doi: 10.1530/ERC-17-0108. Review. PubMed PMID: 28808043.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC,  Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017  Aug 8. PubMed PMID: 28790115; PubMed Central PMCID: PMC5690834.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14. PubMed PMID: 28614298; PubMed Central PMCID: PMC5576182.

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu  F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PubMed PMID: 28591577; PubMed Central PMCID: PMC5675034.

Jhun MA, Geybels MS, Wright JL, Kolb S, April C, Bibikova M, Ostrander EA, Fan JB, Feng Z, Stanford JL. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Oncotarget. 2017 Jun 27;8(26):43035-43047. doi: 10.18632/oncotarget.17428. PubMed PMID: 28496006; PubMed Central PMCID: PMC5522125.

Levesque C, Nelson PS. Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. Cold Spring Harb Perspect Med. 2018 Aug 1;8(8). pii: a030510. doi: 10.1101/cshperspect.a030510. Review. PubMed PMID: 28490538; PubMed Central PMCID: PMC5681439.

Malek R, Gajula RP, Williams RD, Nghiem B, Simons BW, Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, True L, An SS, DeWeese TL, Ross AE, Schaeffer EM, Pienta KJ, Hurley PJ, Morrissey C, Tran PT. TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Res. 2017 Jun 15;77(12):3181-3193. doi: 10.1158/0008-5472.CAN-16-2797. Epub 2017 May 8. PubMed PMID: 28484075; PubMed Central PMCID: PMC5489316.

Lawless M, Gulati R, Tretiakova M. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk  of progression. Histopathology. 2017 Sep;71(3):406-414. doi: 10.1111/his.13247. Epub 2017 Jun 27. PubMed PMID: 28470753; PubMed Central PMCID: PMC5552491.

Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, Lawn S, Gleave ME, Gregory-Evans CY, McIntosh LP, Cox ME, Rennie PS, Cherkasov A. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 2017 Jun 27;8(26):42438-42454. doi: 10.18632/oncotarget.17124. PubMed PMID: 28465491; PubMed Central PMCID: PMC5522078.

Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Mol Cancer Res. 2017 May;15(5):521-531. doi: 10.1158/1541-7786.MCR-16-0315-T. PubMed PMID: 28465296; PubMed Central PMCID: PMC5471626.

Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A, Rubin MA, Shen MM, Abate-Shen C. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. Cancer Discov. 2017 Jul;7(7):736-749. doi:  10.1158/2159-8290.CD 16-1174. Epub 2017 Apr 14. PubMed PMID: 28411207; PubMed Central PMCID: PMC5501744.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB. Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7. PubMed PMID: 28389510; PubMed Central PMCID: PMC5559332.

Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, Abate-Shen C. Co-clinical  Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol. 2017 Oct;72(4):499-506. doi: 10.1016/j.eururo.2017.03.031. Epub 2017 Apr 4. PubMed PMID: 28385453; PubMed Central PMCID: PMC5600823.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31. PubMed PMID: 28364014; PubMed Central PMCID: PMC5540794.

Gomez-Sarosi L, Sun Y, Coleman I, Bianchi-Frias D, Nelson PS. DNA Damage Induces a Secretory Program in the Quiescent TME that Fosters Adverse Cancer Phenotypes. Mol Cancer Res. 2017 Jul;15(7):842-851. doi: 10.1158/1541-7786.MCR-16-0387. Epub 2017 Mar 29. PubMed PMID: 28356331; PubMed Central PMCID: PMC5859576.

Nyquist MD, Prasad B, Mostaghel EA. Harnessing Solute Carrier Transporters for Precision Oncology. Molecules. 2017 Mar 28;22(4). pii: E539. doi: 10.3390/molecules22040539. Review. PubMed PMID: 28350329; PubMed Central PMCID: PMC5570559.

Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.  LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3. PubMed PMID: 28156002; PubMed Central PMCID: PMC5354949.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9. PubMed PMID: 28151719; PubMed Central PMCID: PMC5570479.

Rubicz R, Zhao S, Wright JL, Coleman I, Grasso C, Geybels MS, Leonardson A, Kolb S, April C, Bibikova M, Troyer D, Lance R, Lin DW, Ostrander EA, Nelson PS,  Fan JB, Feng Z, Stanford JL. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Mol Oncol. 2017 Feb;11(2):140-150. doi: 10.1002/1878-0261.12014. Epub 2016 Oct 19. PubMed PMID: 28145099; PubMed Central PMCID: PMC5510189.

Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Androgen  receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168. PubMed PMID: 28038451; PubMed Central PMCID: PMC5354758.

Paul N, Carabet LA, Lallous N, Yamazaki T, Gleave ME, Rennie PS, Cherkasov A. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. J Chem Inf Model. 2016 Dec 27;56(12):2507-2516. doi: 10.1021/acs.jcim.6b00400. Epub 2016 Nov 18. PubMed PMID: 28024400.

Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR, Ittmann M. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget. 2017 Jan 24;8(4):6179-6192. doi: 10.18632/oncotarget.14049. PubMed PMID: 28008155; PubMed Central PMCID: PMC5351622.

Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clin Cancer Res. 2017 May 1;23(9):2301-2312. doi: 10.1158/1078-0432.CCR-16-2054. Epub 2016 Dec 19. PubMed PMID: 27993966; PubMed Central PMCID: PMC5413408.

Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, Higano CS, Morrissey C, Nelson PS, Plymate SR, Dehm SM. Truncation and constitutive activation of the  androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun. 2016 Nov 29;7:13668. doi: 10.1038/ncomms13668. PubMed PMID: 27897170; PubMed Central PMCID: PMC5141345.

Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME,  Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1. PubMed PMID: 27810448; PubMed Central PMCID: PMC5571762.

Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat  A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816. PubMed PMID: 27276681; PubMed Central PMCID: PMC5130036.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7. PubMed PMID: 27765852; PubMed Central PMCID: PMC5136324.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697. PubMed PMID: 27756888; PubMed Central PMCID: PMC5347709.

Geybels MS, McCloskey KD, Mills IG, Stanford JL. Calcium Channel Blocker Use  and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status. Prostate. 2017 Feb;77(3):282-290. doi: 10.1002/pros.23267. Epub 2016 Oct 18. PubMed PMID: 27753122; PubMed Central PMCID: PMC5668682.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14. PubMed PMID: 27742670; PubMed Central PMCID: PMC5296376.

Uo T, Dvinge H, Sprenger CC, Bradley RK, Nelson PS, Plymate SR. Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene. 2017 Mar;36(10):1440-1450. doi: 10.1038/onc.2016.313. Epub 2016 Oct 3. PubMed PMID: 27694897; PubMed Central PMCID: PMC5344735.

Nghiem B, Zhang X, Lam HM, True LD, Coleman I, Higano CS, Nelson PS, Pritchard CC, Morrissey C. Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. Asian J Urol. 2016 Oct;3(4):223-228. doi: 10.1016/j.ajur.2016.09.002. Epub 2016 Sep 12. PubMed PMID: 29264190; PubMed Central PMCID: PMC5730872.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970. PubMed PMID: 27683182; PubMed Central PMCID: PMC5315609.

Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics. 2016 Sep 15;8:97. doi: 10.1186/s13148-016-0260-z. eCollection 2016.  PubMed PMID: 27651837; PubMed Central PMCID: PMC5024414.

Green SM, Kaipainen A, Bullock K, Zhang A, Lucas JM, Matson C, Banks WA, Mostaghel EA. Role of OATP transporters in steroid uptake by prostate cancer cells in vivo. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):20-27. doi: 10.1038/pcan.2016.42. Epub 2016 Sep 20. PubMed PMID: 27645128; PubMed Central PMCID: PMC5762123.

Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, Pfeifer C, Welch I, Wyatt AW, Fazli L, Gleave ME, Jefferies WA. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep. 2016 Sep 13;6:30555. doi: 10.1038/srep30555. PubMed PMID: 27619158; PubMed Central PMCID: PMC5020406.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan  S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6. PubMed PMID: 27433846; PubMed Central PMCID: PMC4986616.

Rizzardi AE, Zhang X, Vogel RI, Kolb S, Geybels MS, Leung YK, Henriksen JC,  Ho SM, Kwak J, Stanford JL, Schmechel SC. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer. Diagn Pathol. 2016 Jul 11;11(1):63. doi: 10.1186/s13000-016-0511-5. PubMed PMID: 27401406; PubMed Central PMCID: PMC4940862.

Martin PL, Yin JJ, Seng V, Casey O, Corey E, Morrissey C, Simpson RM, Kelly  K. Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene. 2017 Jan 26;36(4):525-533. doi: 10.1038/onc.2016.223. Epub 2016 Jul 4. PubMed PMID: 27375016; PubMed Central PMCID: PMC6639059.

Zhao S, Geybels MS, Leonardson A, Rubicz R, Kolb S, Yan Q, Klotzle B, Bibikova M, Hurtado-Coll A, Troyer D, Lance R, Lin DW, Wright JL, Ostrander EA, Fan JB, Feng Z, Stanford JL. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. Clin Cancer Res. 2017 Jan 1;23(1):311-319. doi: 10.1158/1078-0432.CCR-16-0549. Epub 2016 Jun 29. PubMed PMID: 27358489; PubMed Central PMCID: PMC5199634.

Don-Doncow N, Marginean F, Coleman I, Nelson PS, Ehrnström R, Krzyzanowska A, Morrissey C, Hellsten R, Bjartell A. Expression of STAT3 in Prostate Cancer Metastases. Eur Urol. 2017 Mar;71(3):313-316. doi: 10.1016/j.eururo.2016.06.018.  Epub 2016 Jun 22. PubMed PMID: 27344294; PubMed Central PMCID: PMC5624794.

Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21. PubMed PMID: 27324988; PubMed Central PMCID: PMC5549853.

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14. PubMed PMID: 27300548; PubMed Central PMCID: PMC5298886.

Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M. A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer. Prostate. 2016 Oct;76(14):1285-92. doi: 10.1002/pros.23215. Epub 2016 Jun 8. PubMed PMID: 27273062; PubMed Central PMCID: PMC4988926.

Montgomery RB, Plymate SR. AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy? JAMA Oncol. 2016 Nov 1;2(11):1450-1451. doi: 10.1001/jamaoncol.2016.2360. PubMed PMID: 27261766.

Van Allen EM, Robinson D, Morrissey C, Pritchard C, Imamovic A, Carter S, Rosenberg M, McKenna A, Wu YM, Cao X, Chinnaiyan A, Garraway L, Nelson PS. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget. 2016  Aug 16;7(33):52888-52899. doi: 10.18632/oncotarget.9184. PubMed PMID: 27167109; PubMed Central PMCID: PMC5288156.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016 Dec 1;2(12):1598-1606. doi: 10.1001/jamaoncol.2016.0494. PubMed PMID: 27148695; PubMed Central PMCID: PMC5097690.

Shui IM, Wong CJ, Zhao S, Kolb S, Ebot EM, Geybels MS, Rubicz R, Wright JL,  Lin DW, Klotzle B, Bibikova M, Fan JB, Ostrander EA, Feng Z, Stanford JL. Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes. Cancer. 2016 Jul 15;122(14):2168-77. doi: 10.1002/cncr.30045. Epub 2016 May 3. PubMed PMID: 27142338; PubMed Central PMCID: PMC4930391.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3. PubMed PMID: 27136741; PubMed Central PMCID: PMC5536893.

Brocqueville G, Chmelar RS, Bauderlique-Le Roy H, Deruy E, Tian L, Vessella RL, Greenberg NM, Rohrschneider LR, Bourette RP. s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells. Oncotarget. 2016 May 17;7(20):29228-44. doi: 10.18632/oncotarget.8709. PubMed PMID: 27081082; PubMed Central PMCID: PMC5045392.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16. PubMed PMID: 26990456; PubMed Central PMCID: PMC5589183.

Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 Jul 15;22(14):3672-82. doi: 10.1158/1078-0432.CCR-15-2309. Epub 2016 Mar 2. PubMed PMID: 26936914; PubMed Central PMCID: PMC4947432.

Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016 Apr;22(4):369-78. doi: 10.1038/nm.4053. Epub 2016 Feb 29. PubMed PMID: 26928463; PubMed Central PMCID: PMC5045679.

Schweizer MT, Plymate SR. Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer. Expert Opin Ther Targets. 2016 Aug;20(8):903-6. doi: 10.1517/14728222.2016.1159676. Epub 2016 Mar 21. PubMed PMID: 26927611; PubMed Central PMCID: PMC4975933.

Rubicz R, Zhao S, Geybels M, Wright JL, Kolb S, Klotzle B, Bibikova M, Troyer D, Lance R, Ostrander EA, Feng Z, Fan JB, Stanford JL. DNA methylation profiles in African American prostate cancer patients in relation to disease progression. Genomics. 2019 Jan;111(1):10-16. doi: 10.1016/j.ygeno.2016.02.004. Epub 2016 Feb 21. PubMed PMID: 26902887; PubMed Central PMCID: PMC4992660.

Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I, Nelson PS, Corey E, Peehl DM. Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer. Clin Exp Metastasis. 2016 Apr;33(4):325-37. doi: 10.1007/s10585-016-9781-2. Epub 2016 Feb 12. PubMed PMID: 26873136.

Shui IM, Kolb S, Hanson C, Sutcliffe S, Rider JR, Stanford JL. Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate. 2016 May;76(7):620-3. doi: 10.1002/pros.23153. Epub 2016 Jan 28. PubMed PMID: 26818005; PubMed Central PMCID: PMC5002353.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 2016 Jan 26;17:10. doi: 10.1186/s13059-015-0864-1. PubMed PMID: 26813233; PubMed Central PMCID: PMC4729137.

Schade GR, Holt SK, Zhang X, Song D, Wright JL, Zhao S, Kolb S, Lam HM, Levin L, Leung YK, Ho SM, Stanford JL. Prostate Cancer Expression Profiles of Cytoplasmic ERβ1 and Nuclear ERβ2 are Associated with Poor Outcomes following Radical Prostatectomy. J Urol. 2016 Jun;195(6):1760-6. doi: 10.1016/j.juro.2015.12.101. Epub 2016 Jan 22. PubMed PMID: 26804755; PubMed Central PMCID: PMC4871721.

Zhang A, Zhang J, Plymate S, Mostaghel EA. Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer. 2016 Apr;7(2):104-13. doi: 10.1007/s12672-016-0250-9. Epub 2016 Jan 21. Review. PubMed PMID: 26797685; PubMed Central PMCID: PMC4859429.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res. 2016 Apr;14(4):324-31. doi:  10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20. PubMed PMID: 26792867; PubMed Central PMCID: PMC4834259.

Meaburn KJ, Agunloye O, Devine M, Leshner M, Roloff GW, True LD, Misteli T.  Tissue-of-origin-specific gene repositioning in breast and prostate cancer. Histochem Cell Biol. 2016 Apr;145(4):433-46. doi: 10.1007/s00418-015-1401-8. Epub 2016 Jan 20. PubMed PMID: 26791532; PubMed Central PMCID: PMC4795970.

Bianchi-Frias D, Basom R, Delrow JJ, Coleman IM, Dakhova O, Qu X, Fang M, Franco OE, Ericson NG, Bielas JH, Hayward SW, True L, Morrissey C, Brown L, Bhowmick NA, Rowley D, Ittmann M, Nelson PS. Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. Mol Cancer Res. 2016 Apr;14(4):374-84. doi: 10.1158/1541-7786.MCR-15-0330. Epub 2016 Jan 11. PubMed PMID: 26753621; PubMed Central PMCID: PMC5582956.

Qu X, Jeldres C, Glaskova L, Friedman C, Schroeder S, Nelson PS, Porter C, Fang M. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn. 2016 Mar;18(2):215-24. doi: 10.1016/j.jmoldx.2015.10.001. Epub 2016 Jan 2. PubMed PMID: 26752304; PubMed Central PMCID: PMC4816705.

Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 Jun;69(6):992-5. doi: 10.1016/j.eururo.2015.11.022. Epub 2015 Dec 24. PubMed PMID: 26724258; PubMed Central PMCID: PMC4909531.

Geybels MS, Alumkal JJ, Luedeke M, Rinckleb A, Zhao S, Shui IM, Bibikova M,  Klotzle B, van den Brandt PA, Ostrander EA, Fan JB, Feng Z, Maier C, Stanford JL. Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. Clin Epigenetics. 2015 Dec 12;7:128. doi: 10.1186/s13148-015-0161-6. eCollection 2015. PubMed PMID: 26692910; PubMed Central PMCID: PMC4676897.

Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, Coleman R, Montgomery B, Lange PH, Roudier M, Higano CS, Bielas JH, Nelson PS, Vessella RL, Morrissey C. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis. 2016 Mar;33(3):239-48. doi: 10.1007/s10585-015-9773-7. Epub 2015 Dec 14. PubMed PMID: 26667932; PubMed Central PMCID: PMC4777655.

Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene. 2016 Jul 21;35(29):3781-95. doi: 10.1038/onc.2015.444. Epub 2015 Dec 7. PubMed PMID: 26640144; PubMed Central PMCID: PMC4896852.

Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON. Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30. PubMed PMID: 26621741; PubMed Central PMCID: PMC4720329.

Wu Y, Schoenborn JR, Morrissey C, Xia J, Larson S, Brown LG, Qu X, Lange PH, Nelson PS, Vessella RL, Fang M. High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn. 2016 Jan;18(1):131-43. doi: 10.1016/j.jmoldx.2015.08.004. Epub 2015 Nov 20. PubMed PMID: 26607774; PubMed Central PMCID: PMC4715223.

Leshner M, Devine M, Roloff GW, True LD, Misteli T, Meaburn KJ. Locus-specific gene repositioning in prostate cancer. Mol Biol Cell. 2016 Jan 15;27(2):236-46. doi: 10.1091/mbc.E15-05-0280. Epub 2015 Nov 12. PubMed PMID: 26564800; PubMed Central PMCID: PMC4713128.

Wright JL, Chéry L, Holt S, Lin DW, Luedeke M, Rinckleb AE, Maier C, Stanford JL. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):53-6. doi: 10.1038/pcan.2015.49. Epub 2015 Oct 27. PubMed PMID: 26503111; PubMed Central PMCID: PMC4942258.

Morrissey C, Vessella RL, Lange PH, Lam HM. The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med (Berl). 2016 Mar;94(3):259-65. doi: 10.1007/s00109-015-1353-4. Epub 2015 Oct 21. Review. PubMed PMID: 26489605; PubMed Central PMCID: PMC4803572.

Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2016 Jun;13(6):335-47.  doi: 10.1038/nrclinonc.2015.175. Epub 2015 Oct 20. Review. PubMed PMID: 26483300; PubMed Central PMCID: PMC4838548.

Geybels MS, Zhao S, Wong CJ, Bibikova M, Klotzle B, Wu M, Ostrander EA, Fan JB, Feng Z, Stanford JL. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. Prostate. 2015 Dec;75(16):1941-50. doi: 10.1002/pros.23093. Epub 2015 Sep 18. PubMed PMID: 26383847; PubMed Central PMCID: PMC4928710.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR,  Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; CanaryPASS Investigators. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29. PubMed PMID: 26327354; PubMed Central PMCID: PMC4970462.

Mostaghel EA, Zhang A, Plymate S. UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved? Eur Urol. 2016 Apr;69(4):610-612. doi: 10.1016/j.eururo.2015.08.025. Epub 2015 Aug 28. PubMed PMID: 26318705.

Prencipe M, O'Neill A, O'Hurley G, Nguyen LK, Fabre A, Bjartell A, Gallagher WM, Morrissey C, Kay EW, Watson RW. Relationship between serum response factor and androgen receptor in prostate cancer. Prostate. 2015 Nov;75(15):1704-17. doi: 10.1002/pros.23051. Epub 2015 Aug 7. PubMed PMID: 26250344; PubMed Central PMCID: PMC4579008.

Winters B, Plymate S, Zeliadt SB, Holt S, Zhang X, Hu E, Lin DW, Morrissey C, Wooldridge B, Gore JL, Porter MP, Wright JL. Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate. 2015 Nov;75(15):1694-703. doi: 10.1002/pros.23049. Epub 2015 Jul 22. PubMed PMID: 26201966; PubMed Central PMCID: PMC4578998.

Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson PS, Campisi J. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015 Aug;17(8):1049-61. doi: 10.1038/ncb3195. Epub 2015 Jul 6. PubMed PMID: 26147250; PubMed Central PMCID: PMC4691706.

Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome Med. 2015 May 15;7(1):45. doi: 10.1186/s13073-015-0168-9. eCollection 2015. PubMed PMID: 26113877; PubMed Central PMCID: PMC4480902.

Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM. Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy. PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015.  PubMed PMID: 26090669; PubMed Central PMCID: PMC4475050.

Xia Y, Wang M, Beraldi E, Cong M, Zoubeidi A, Gleave M, Peng L. A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. Anticancer Agents Med Chem. 2015;15(10):1333-40. PubMed PMID: 26081200.

Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit  R, Corey E, Chéry L, Lakely B, Higano CS, Montgomery B, Roudier M, Lange PH, Nelson PS, Vessella RL, Morrissey C. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Oct 15;21(20):4698-708. doi: 10.1158/1078-0432.CCR-15-0157. Epub 2015 Jun 12. PubMed PMID: 26071481; PubMed Central PMCID: PMC4609255.

Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD, Nelson PS, Vasioukhin V. ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors. Cancer Cell. 2015 Jun 8;27(6):797-808. doi: 10.1016/j.ccell.2015.05.005. PubMed PMID: 26058078; PubMed Central PMCID: PMC4461839.

Yu SH, Zheng Q, Esopi D, Macgregor-Das A, Luo J, Antonarakis ES, Drake CG, Vessella R, Morrissey C, De Marzo AM, Sfanos KS. A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1175-84. doi: 10.1158/2326-6066.CIR-15-0013. Epub 2015 Jun 5. PubMed PMID: 26048576; PubMed Central PMCID: PMC4596748.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa  ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul  16;162(2):454. PubMed PMID: 26000489; PubMed Central PMCID: PMC4484602.

Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, Lin DW, Nelson PS, Ostrander EA, Feng Z, Fan JB, Stanford JL. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. Prostate. 2015 Sep;75(13):1354-62. doi: 10.1002/pros.23016. Epub 2015 May 18. PubMed PMID: 25990700; PubMed Central PMCID: PMC4992473.

Arnold RS, Fedewa SA, Goodman M, Osunkoya AO, Kissick HT, Morrissey C, True LD, Petros JA. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Bone.2015 Sep;78:81-6. doi: 10.1016/j.bone.2015.04.046. Epub 2015 May 5. PubMed PMID: 25952970; PubMed Central PMCID: PMC4466124.

Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. A multicenter study shows  PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4. PubMed PMID: 25939393; PubMed Central PMCID: PMC4475421.

Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status. Am J Epidemiol. 2015 May 1;181(9):706-13. doi: 10.1093/aje/kwu344. Epub 2015 Apr 7. PubMed PMID: 25852077; PubMed Central PMCID: PMC4408951.

Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol.  2015 May 10;33(14):1601-8. doi: 10.1200/JCO.2014.59.4127. Epub 2015 Apr 6. PubMed PMID: 25847934; PubMed Central PMCID: PMC4417730.

Etzioni R, Gulati R, Lin DW. Measures of survival benefit in cancer drug development and their limitations. Urol Oncol. 2015 Mar;33(3):122-7. doi: 10.1016/j.urolonc.2014.11.002. Review. PubMed PMID: 25813143; PubMed Central PMCID: PMC4403641.

Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15;75(10):1944-8. doi: 10.1158/0008-5472.CAN-14-3602. Epub 2015 Mar 25. PubMed PMID: 25808865; PubMed Central PMCID: PMC4433564.

Ghajar CM. Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 2015 Apr;15(4):238-47. doi: 10.1038/nrc3910. Review. PubMed PMID: 25801619; PubMed Central PMCID: PMC4842412.

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Konodi MA, Kurland BF, Marck BT, Matsumoto AM, Dalkin BL, Montgomery RB. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):236-43. doi: 10.1016/j.ijrobp.2015.01.020. Epub 2015 Mar 12. PubMed PMID: 25772183; PubMed Central PMCID: PMC4459893.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20. PubMed PMID: 25600186; PubMed Central PMCID: PMC4430366.

Huber RM, Lucas JM, Gomez-Sarosi LA, Coleman I, Zhao S, Coleman R, Nelson PS. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. Oncotarget. 2015 Feb 10;6(4):2134-47. PubMed PMID: 25575823; PubMed Central PMCID: PMC4385841.

Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME. Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775. PubMed PMID: 25503391; PubMed Central PMCID:  PMC4275590.

Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget. 2015 Jan 1;6(1):288-304. PubMed PMID: 25481872; PubMed Central PMCID: PMC4381595.

Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival  after radical prostatectomy. Urology. 2014 Dec;84(6):1427-32. doi: 10.1016/j.urology.2014.07.059. PubMed PMID: 25432832.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014. PubMed PMID: 25356728; PubMed Central PMCID: PMC4214744.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True  LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.  PubMed PMID: 25320358; PubMed Central PMCID: PMC4359958.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13. PubMed PMID: 25311217; PubMed Central PMCID: PMC4226804.

Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget. 2014 Oct 30;5(20):9939-51. PubMed PMID: 25301725; PubMed Central PMCID: PMC4259449.

Bianchi-Frias D, Hernandez SA, Coleman R, Wu H, Nelson PS. The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma. Mol Cancer Res. 2015 Feb;13(2):339-47. doi: 10.1158/1541-7786.MCR-14-0262. Epub 2014 Oct 8. PubMed PMID: 25298407; PubMed Central PMCID: PMC4527302.

Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer. 2014;21(6):903-14. doi: 10.1530/ERC-14-0402. Epub 2014 Oct 6. PubMed PMID: 25287069; PubMed Central  PMCID: PMC4233119.

Lu ZX, Huang Q, Park JW, Shen S, Lin L, Tokheim CJ, Henry MD, Xing Y. Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization. Mol Cancer Res. 2015 Feb;13(2):305-18. doi: 10.1158/1541-7786.MCR-14-0366. Epub 2014 Oct 1. PubMed PMID: 25274489; PubMed Central PMCID: PMC4336826.

Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14888-93. doi: 10.1073/pnas.1408301111. Epub 2014 Sep 29. PubMed PMID: 25267620; PubMed Central PMCID: PMC4205618.

Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014 Sep 25;5:4988. doi: 10.1038/ncomms5988. PubMed PMID: 25255306; PubMed Central PMCID: PMC4176888.

Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, Yu EY. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer. 2015 Feb;13(1):10-6. doi: 10.1016/j.clgc.2014.08.003. Epub 2014 Aug 10. PubMed PMID: 25242417; PubMed Central PMCID: PMC4289425.

Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One. 2014 Sep 8;9(9):e104271. doi: 10.1371/journal.pone.0104271. eCollection 2014. PubMed PMID: 25198178; PubMed Central PMCID: PMC4157741.

Cho E, Montgomery RB, Mostaghel EA. Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology. 2014 Nov;155(11):4124-32. doi: 10.1210/en.2014-1337. Epub 2014 Aug 22. Review. PubMed PMID: 25147980; PubMed Central PMCID: PMC4298565.

Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13. PubMed PMID: 25122198; PubMed Central PMCID: PMC4409786.

Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ. SOX2 expression in the  developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis.  2014 Dec;17(4):301-9. doi: 10.1038/pcan.2014.29. Epub 2014 Aug 5. PubMed PMID: 25091041; PubMed Central PMCID: PMC4227931.

Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015 May;67(5):866-73. doi: 10.1016/j.eururo.2014.06.042. Epub 2014 Jul 10. PubMed PMID: 25018037.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM. Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype. Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3. PubMed PMID: 24998678; PubMed Central PMCID: PMC4112013.

Yin J, Liu YN, Tillman H, Barrett B, Hewitt S, Ylaya K, Fang L, Lake R, Corey E, Morrissey C, Vessella R, Kelly K. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res. 2014 Aug 15;74(16):4306-17. doi: 10.1158/0008-5472.CAN-13-3233. Epub 2014 Jun 26. PubMed PMID: 24970477; PubMed Central PMCID: PMC4429795.

Mostaghel EA. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci. 2014 Jun 3;10(6):602-13. doi:  10.7150/ijbs.8844. eCollection 2014. Review. PubMed PMID: 24948873; PubMed Central PMCID: PMC4062953.

Lam HM, Vessella RL, Morrissey C. The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow. Drug Discov Today Technol.  2014 Mar;11:41-7. doi: 10.1016/j.ddtec.2014.02.002. Review. PubMed PMID: 24847652; PubMed Central PMCID: PMC4412595.

Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9. PubMed PMID: 24807866; PubMed Central PMCID: PMC4322920.

Van Hook K, Huang T, Alumkal JJ. Orteronel for the treatment of prostate cancer. Future Oncol. 2014 Apr;10(5):803-11. doi: 10.2217/fon.14.35. PubMed PMID: 24799061; PubMed Central PMCID: PMC4148348.

Sprenger CC, Plymate SR. The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Cancer. 2014 Aug;5(4):207-17. doi: 10.1007/s12672-014-0177-y. Epub 2014 May 6. Review. PubMed PMID: 24798453; PubMed Central PMCID: PMC4308035.

Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):57-63. Review. PubMed PMID: 24775725; PubMed Central PMCID: PMC4139288.

Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget. 2014 Mar 30;5(6):1646-56. PubMed PMID: 24722067; PubMed Central PMCID: PMC4039237.

Stott-Miller M, Zhao S, Wright JL, Kolb S, Bibikova M, Klotzle B, Ostrander  EA, Fan JB, Feng Z, Stanford JL. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1331-9. doi: 10.1158/1055-9965.EPI-13-1000. Epub  2014 Apr 9. PubMed PMID: 24718283; PubMed Central PMCID: PMC4082437.

Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong X. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 2014 Mar 24;9(3):e92714. doi: 10.1371/journal.pone.0092714. eCollection 2014. PubMed PMID: 24664419; PubMed Central PMCID: PMC3963951.

Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST, Wu H. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 2014 Jun;34(11):2017-28. doi: 10.1128/MCB.00090-14. Epub 2014 Mar 24. Erratum in: Mol Cell Biol. 2014 Sep;34(17):3354. PubMed PMID: 24662052; PubMed Central PMCID: PMC4019050.

Montgomery B, Cheng HH, Drechsler J, Mostaghel EA. Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl. 2014 May-Jun;16(3):354-8. doi: 10.4103/1008-682X.125392. Review. PubMed PMID: 24625881; PubMed Central PMCID: PMC4023359.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E,  Nanus DM, Plymate SR, Giannakakou P. Androgen receptor splice variants determine  taxane sensitivity in prostate cancer. Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20. PubMed PMID: 24556717; PubMed Central PMCID: PMC4012562.

Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL. Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162. PubMed PMID: 24525503; PubMed Central PMCID: PMC4428570.

Tarnow C, Engels G, Arendt A, Schwalm F, Sediri H, Preuss A, Nelson PS, Garten W, Klenk HD, Gabriel G, Böttcher-Friebertshäuser E. TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. J Virol. 2014 May;88(9):4744-51. doi: 10.1128/JVI.03799-13. Epub 2014 Feb 12. PubMed PMID: 24522916; PubMed Central PMCID: PMC3993819.

Mostaghel EA. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res. 2014 Jan 28;6:39-51. doi: 10.2147/CMAR.S39318. eCollection 2014. Review. PubMed PMID: 24501545; PubMed Central PMCID: PMC3912049.

True LD. Methodological requirements for valid tissue-based biomarker studies that can be used in clinical practice. Virchows Arch. 2014 Mar;464(3):257-63. doi: 10.1007/s00428-013-1531-0. Epub 2014 Feb 1. Review. PubMed PMID: 24487786; PubMed Central PMCID: PMC4009398.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21. PubMed PMID: 24449822; PubMed Central PMCID: PMC4022291.

Lamoureux F, Thomas C, Yin MJ, Fazli L, Zoubeidi A, Gleave ME. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol. 2014 Jul;66(1):145-55. doi: 10.1016/j.eururo.2013.12.019. Epub 2013 Dec 29. Erratum in: Eur Urol. 2016 Jul;70(1):e27-e28. PubMed PMID: 24411988; PubMed Central PMCID: PMC4079118.

Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM. Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res. 2014 Mar 1;20(5):1306-12. doi: 10.1158/1078-0432.CCR-13-1775. Epub 2013 Dec 18. PubMed PMID: 24352642; PubMed Central PMCID: PMC3947466.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9. PubMed PMID: 24323034; PubMed Central PMCID: PMC3887479.

Wright JL, Hansten PD, Stanford JL. Is digoxin use for cardiovascular disease associated with risk of prostate cancer? Prostate. 2014 Jan;74(1):97-102. doi: 10.1002/pros.22733. Epub 2013 Sep 21. PubMed PMID: 24318956; PubMed Central PMCID: PMC3935420.

Mostaghel EA, Plymate SR, Montgomery B. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit. Clin Cancer Res. 2014 Feb 15;20(4):791-8. doi: 10.1158/1078-0432.CCR-12-3601. Epub 2013 Dec 4. PubMed PMID: 24305618; PubMed Central PMCID: PMC3944407.

Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2. Epub  2013 Nov 17. PubMed PMID: 24242705; PubMed Central PMCID: PMC3946934.

Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671. eCollection 2013. PubMed PMID: 24098661; PubMed Central PMCID: PMC3787014.

Stott-Miller M, Wright JL, Stanford JL. MSMB gene variant alters the association between prostate cancer and number of sexual partners. Prostate. 2013 Dec;73(16):1803-9. doi: 10.1002/pros.22719. Epub 2013 Aug 23. PubMed PMID: 24037734; PubMed Central PMCID: PMC3992835.

Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia. 2013 Sep;15(9):1009-17. PubMed PMID: 24027426; PubMed Central PMCID: PMC3769880.

Zrazhevskiy P, True LD, Gao X. Multicolor multicycle molecular profiling with quantum dots for single-cell analysis. Nat Protoc. 2013 Oct;8(10):1852-69. doi: 10.1038/nprot.2013.112. Epub 2013 Sep 5. PubMed PMID: 24008381; PubMed Central PMCID: PMC4108347.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013 Oct;10(10):1003-5. doi: 10.1038/nmeth.2633. Epub 2013 Sep 1. PubMed PMID: 23995387; PubMed Central PMCID: PMC4118677.

Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013 Aug 29;154(5):1074-1084. doi: 10.1016/j.cell.2013.07.029. PubMed PMID: 23993097; PubMed Central PMCID: PMC3931012.

Mostaghel EA. Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol. 2013 Sep;2(3):212-227. PubMed PMID: 25379460; PubMed Central PMCID: PMC4219921.

Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013 Oct;37(5):666-70. doi: 10.1016/j.canep.2013.07.005. Epub 2013 Aug 20. PubMed PMID: 23972671; PubMed Central PMCID: PMC3864767.

Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One. 2013 Jul 30;8(7):e69239. doi: 10.1371/journal.pone.0069239. Print 2013. PubMed PMID: 23935962; PubMed Central PMCID: PMC3728349.

Geybels MS, Neuhouser ML, Wright JL, Stott-Miller M, Stanford JL. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control. 2013 Nov;24(11):1947-54. doi: 10.1007/s10552-013-0270-5. Epub 2013 Aug 2. PubMed PMID: 23907772; PubMed Central PMCID: PMC3859380.

Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene. 2014 Jun 12;33(24):3140-50. doi: 10.1038/onc.2013.284. Epub 2013 Jul 15. PubMed PMID:23851510; PubMed Central PMCID: PMC4553036.

Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TM. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol. 2013 Nov;138:281-9. doi: 10.1016/j.jsbmb.2013.06.014. Epub 2013 Jul 10. PubMed PMID: 23851165; PubMed Central PMCID: PMC3866616.

Fitzgerald LM, Kumar A, Boyle EA, Zhang Y, McIntosh LM, Kolb S, Stott-Miller M, Smith T, Karyadi DM, Ostrander EA, Hsu L, Shendure J, Stanford JL. Germline missense variants in the BTNL2 gene are associated with prostate cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1520-8. doi: 10.1158/1055-9965.EPI-13-0345. Epub 2013 Jul 5. PubMed PMID: 23833122; PubMed Central PMCID: PMC3769499.

Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR. Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol. 2013 Sep 1;178(5):741-51. doi: 10.1093/aje/kwt044. Epub 2013 Jun 28. PubMed PMID: 23813705; PubMed Central PMCID: PMC3755644.

Wright JL, Plymate S, D'Oria-Cameron A, Bain C, Haugk K, Xiao L, Lin DW, Stanford JL, McTiernan A. A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate. 2013 Sep;73(12):1345-51. doi: 10.1002/pros.22682. Epub 2013 Jun 15. PubMed PMID: 23775525; PubMed Central PMCID: PMC3767289.

Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6. PubMed PMID: 23740600; PubMed Central PMCID: PMC3720815.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3. PubMed PMID: 23722902; PubMed Central PMCID: PMC3696543.

Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin Cancer Res. 2013 Aug 1;19(15):4058-66. doi: 10.1158/1078-0432.CCR-12-3606. Epub 2013 May 23. Review. PubMed PMID: 23704282; PubMed Central PMCID: PMC3732571.

227: Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget. 2013 May;4(5):691-704. PubMed PMID: 23674566; PubMed Central PMCID: PMC3742830.

Yu Y, Liu L, Xie N, Xue H, Fazli L, Buttyan R, Wang Y, Gleave M, Dong X. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab. 2013 Jul;98(7):2887-96. doi: 10.1210/jc.2012-4000. Epub 2013 May 10. PubMed PMID: 23666965; PubMed Central PMCID: PMC4078099.

Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.  Prostate. 2013 Aug;73(11):1214-22. doi: 10.1002/pros.22671. Epub 2013 Apr 30. PubMed PMID: 23633265; PubMed Central PMCID: PMC3967507.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013 May;98(5): E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26. PubMed PMID: 23533230; PubMed Central PMCID: PMC4430583.

Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res. 2013 May 1;19(9):2442-50. doi: 10.1158/1078-0432.CCR-12-3283. Epub 2013 Mar 20. PubMed PMID: 23515404; PubMed Central PMCID: PMC3674574.

Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, Porter C, Nelson PS. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res. 2013 Jun;11(6):568-78. doi: 10.1158/1541-7786.MCR-12-0710. Epub 2013 Mar 14. PubMed PMID: 23493267; PubMed Central PMCID: PMC3687002.

Wright JL, Plymate SR, Porter MP, Gore JL, Lin DW, Hu E, Zeliadt SB. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun;16(2):204-8. doi: 10.1038/pcan.2013.5. Epub 2013 Mar 5. PubMed PMID: 23459096; PubMed Central PMCID: PMC3753020.

Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, Diamandis EP. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics. 2013 Jun;12(6):1589-601. doi: 10.1074/mcp.M112.023887. Epub 2013 Feb 26. PubMed PMID: 23443136; PubMed Central  PMCID: PMC3675816.

Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol. 2013 Jul;230(3):291-7. doi: 10.1002/path.4180. PubMed PMID: 23420560; PubMed Central PMCID: PMC3926514.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24. PubMed PMID: 23352841; PubMed Central PMCID: PMC3632390.

Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M, Kim SR, Bagryanova L, Horvath S, Chia D, Goodglick L, Liu AY. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol. 2013 Jun;26(6):849-59. doi: 10.1038/modpathol.2012.238. Epub 2013 Jan 25. PubMed PMID: 23348903; PubMed Central PMCID: PMC3638070.

Stott-Miller M, Neuhouser ML, Stanford JL. Consumption of deep-fried foods and risk of prostate cancer. Prostate. 2013 Jun;73(9):960-9. doi: 10.1002/pros.22643. Epub 2013 Jan 17. PubMed PMID: 23335051; PubMed Central PMCID: PMC3756514.

Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B, Corey E, Nelson PS, Vessella RL, Morrissey C. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013 Jun;73(9):932-40. doi: 10.1002/pros.22639. Epub 2013 Jan 17. PubMed PMID: 23334979; PubMed Central PMCID: PMC4214278.

Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS, Porter CR. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate. 2013 Jun;73(9):905-12. doi: 10.1002/pros.22636. Epub 2013 Jan 17. PubMed PMID: 23334893; PubMed Central PMCID: PMC3677047.

Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL. Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis. 2013 Jun;30(5):569-78. doi: 10.1007/s10585-012-9561-6. Epub 2012 Dec 15. PubMed PMID: 23242739; PubMed Central PMCID: PMC3736758.

Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604. PubMed PMID: 23239736; PubMed Central PMCID: PMC3625962.

Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J,  Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan;20(1):39-44. doi: 10.1097/PAP.0b013e31827b665b. Review. PubMed PMID: 23232570; PubMed Central PMCID: PMC3535290.

Esser AK, Miller MR, Huang Q, Meier MM, Beltran-Valero de Bernabé D, Stipp CS, Campbell KP, Lynch CF, Smith BJ, Cohen MB, Henry MD. Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer. J Biol Chem. 2013 Jan 25;288(4):2132-42. doi: 10.1074/jbc.M112.432807. Epub 2012 Dec 6. PubMed PMID: 23223448; PubMed Central PMCID: PMC3554886.

Alumkal JJ, Herman JG. Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. Cancer Discov. 2012 Nov;2(11):979-81. doi: 10.1158/2159-8290.CD-12-0392. PubMed PMID: 23148372; PubMed Central PMCID: PMC3661413.

Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, Stanford JL, Peters U. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate. 2013 May;73(7):734-42. doi: 10.1002/pros.22617. Epub 2012 Nov 9. PubMed PMID: 23143801; PubMed Central PMCID: PMC3859305.

Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, Ostrander EA. HOXB13 mutations in a population-based, case-control study of prostate cancer. Prostate. 2013 May;73(6):634-41. doi: 10.1002/pros.22604. Epub 2012 Nov 5. PubMed PMID: 23129385; PubMed Central PMCID: PMC3612366.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH. NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26. PubMed PMID: 23107099; PubMed Central PMCID: PMC4452955.

Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res. 2013 Feb;28(2):333-40. doi: 10.1002/jbmr.1749. PubMed PMID: 22936276; PubMed Central PMCID: PMC3547166.

Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, Diamandis EP. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate  cancer. J Biol Chem. 2012 Oct 5;287(41):34019-31. doi: 10.1074/jbc.M112.384438. Epub 2012 Aug 20. PubMed PMID: 22908226; PubMed Central PMCID: PMC3464512.

FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat. 2013 Jan;34(1):149-56. doi: 10.1002/humu.22176. Epub 2012 Oct 4. PubMed PMID: 22887727; PubMed Central PMCID: PMC3532957.

Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012 Sep;18(9):1359-68. PubMed PMID:  22863786; PubMed Central PMCID: PMC3677971.

Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, Coleman IM, Nelson PS, Vessella RL, Davis RJ, Plymate SR, Mercurio  AM. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9. PubMed PMID: 22777769; PubMed Central PMCID: PMC4205964.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards  J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18. PubMed PMID: 22710436; PubMed Central PMCID: PMC3415705.

Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME. Cotargeting stress-activated Hsp27 and autophagy  as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Mol Cancer Ther. 2012 Aug;11(8):1661-71. doi: 10.1158/1535-7163.MCT-12-0072. Epub 2012 Jun 6. PubMed PMID: 22675041; PubMed Central PMCID: PMC4128402.

Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WJ, Page ST. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab. 2012 Aug;97(8):2809-17. doi: 10.1210/jc.2012-1536. Epub 2012 Jun 1. PubMed PMID: 22659250; PubMed Central PMCID: PMC3410271.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP,  White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM,  Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279. PubMed PMID: 22610119; PubMed Central PMCID: PMC3673022.

Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12. PubMed PMID: 22583636; PubMed Central PMCID: PMC3473078.

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047. PubMed PMID: 22553170; PubMed Central PMCID: PMC3659819.

Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, Stanford JL. Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate. 2013 Jan;73(1):1-10. doi: 10.1002/pros.22534. Epub 2012 May 1. PubMed PMID: 22549291; PubMed Central PMCID: PMC3544476.

Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012 Apr 18;13(5):358-69. doi: 10.1038/nrg3198. Review. PubMed PMID: 22510765; PubMed Central PMCID: PMC4517822.

Rubinow KB, Vaisar T, Tang C, Matsumoto AM, Heinecke JW, Page ST. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res. 2012 Jul;53(7):1376-83. doi: 10.1194/jlr.P026005. Epub 2012 Apr 13. PubMed PMID: 22504910; PubMed Central PMCID: PMC3371249.

Yu EY, Kuo KF, Gulati R, Chen S, Gambol TE, Hall SP, Jiang PY, Pitzel P, Higano CS. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. J Clin Oncol. 2012 May 20;30(15):1864-70. doi: 10.1200/JCO.2011.38.3745.  Epub 2012 Apr 9. PubMed PMID: 22493411; PubMed Central PMCID: PMC3383183.

White TA, Kwon EM, Fu R, Lucas JM, Ostrander EA, Stanford JL, Nelson PS. The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate. 2012 Nov;72(15):1622-7. doi: 10.1002/pros.22515. Epub 2012 Apr 2. PubMed PMID: 22473857; PubMed Central PMCID: PMC3532925.

Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13. doi: 10.1016/j.mce.2011.09.046. Epub 2012 Mar 20. Review. PubMed PMID: 22453214; PubMed Central PMCID: PMC4124858.

Liu AY, Vêncio RZ, Page LS, Ho ME, Loprieno MA, True LD. Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes. Cell Tissue Res. 2012 Jun;348(3):589-600. doi: 10.1007/s00441-012-1383-y. Epub 2012 Mar 20. PubMed PMID: 22427119; PubMed Central PMCID: PMC3367057.

Wright JL, Lin DW, Stanford JL. Circumcision and the risk of prostate cancer. Cancer. 2012 Sep 15;118(18):4437-43. doi: 10.1002/cncr.26653. Epub 2012 Mar 12. PubMed PMID: 22411189; PubMed Central PMCID: PMC3376675.

Gordon RR, Nelson PS. Cellular senescence and cancer chemotherapy resistance. Drug Resist Updat. 2012 Feb-Apr;15(1-2):123-31. doi: 10.1016/j.drup.2012.01.002. Epub 2012 Feb 23. Review. PubMed PMID: 22365330; PubMed Central PMCID: PMC3348393.

Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol. 2012 May;22(3):190-6. doi: 10.1097/MOU.0b013e3283519b58. Review. PubMed PMID: 22328019.

Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012 May;24(3):251-7. doi: 10.1097/CCO.0b013e32835105b3. Review. PubMed PMID: 22327838; PubMed Central PMCID: PMC4161359.

Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Jones SJ, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Volik SV, Collins CC. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2012 May;227(1):53-61. doi: 10.1002/path.3987. Epub 2012 Mar 21. PubMed PMID: 22294438; PubMed Central PMCID: PMC3768138.

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30. PubMed PMID: 22290877; PubMed Central PMCID: PMC3900026.

Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7(1):e30062. doi: 10.1371/journal.pone.0030062. Epub 2012 Jan 18. PubMed PMID: 22279565; PubMed Central PMCID: PMC3261168.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA,  Demichelis F, Beltran H, Hirst M, Marra M, Maher CA, Chinnaiyan AM, Gleave M, Bertino JR, Lubin M, Wang Y. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther. 2012 Mar;11(3):775-83. doi: 10.1158/1535-7163.MCT-11-0826. Epub 2012 Jan 17. PubMed PMID: 22252602; PubMed Central PMCID: PMC3691697.

Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012 Feb 14;106(4):768-74. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12. PubMed PMID: 22240788; PubMed Central PMCID: PMC3322952.

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012 Mar;5(3):492-497. doi: 10.1158/1940-6207.CAPR-11-0370. Epub 2011 Dec 12. PubMed PMID: 22158052; PubMed Central PMCID: PMC4186243.

Austin RJ, Smidansky HM, Holstein CA, Chang DK, Epp A, Josephson NC, Martin DB. Proteomic analysis of the androgen receptor via MS-compatible purification of biotinylated protein on streptavidin resin. Proteomics. 2012 Jan;12(1):43-53. doi: 10.1002/pmic.201100348. Epub 2011 Dec 12. PubMed PMID: 22116683; PubMed Central PMCID: PMC3544294.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17. PubMed PMID: 22114732; PubMed Central PMCID: PMC3219707.

Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18;20(4):457-71. doi: 10.1016/j.ccr.2011.09.001. PubMed PMID: 22014572; PubMed Central PMCID: PMC3225024.

Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci  U S A. 2011 Oct 11;108(41):17087-92. doi: 10.1073/pnas.1108745108. Epub 2011 Sep 26. PubMed PMID: 21949389; PubMed Central PMCID: PMC3193229.

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J, Zarour L, Higano C, True LD, Vessella RL, Wilmot B, Bottomly D, McWeeney SK, Bova GS, Partin AW, Mori M, Alumkal J. A DNA methylation microarray based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 2011 Oct 1;6(10):1248-56. doi: 10.4161/epi.6.10.17727. Epub 2011 Oct 1. PubMed PMID: 21946329; PubMed Central PMCID: PMC3225842.

Mostaghel EA, Plymate S. New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am. 2011 Sep;40(3):625-42, x. doi: 10.1016/j.ecl.2011.05.013. Epub 2011 Jul 14. Review. PubMed PMID: 21889725; PubMed Central PMCID: PMC3167094.

Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15;71(20):6503-13. doi: 10.1158/0008-5472.CAN-11-0532. Epub 2011 Aug 25. PubMed PMID: 21868758; PubMed Central PMCID: PMC3209585.

Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36. doi: 10.1158/1055-9965.EPI-11-0236. Epub 2011 Aug 16. PubMed PMID: 21846818; PubMed Central PMCID: PMC3169727.

Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011 Sep 15;17(18):5913-25. doi: 10.1158/1078-0432.CCR-11 0728. Epub 2011 Aug 1. PubMed PMID: 21807635; PubMed Central PMCID: PMC3184252.

Nguyen HM, Corey E. Methodology to investigate androgen-sensitive and castration-resistant human prostate cancer xenografts in preclinical setting. Methods Mol Biol. 2011;776:295-312. doi: 10.1007/978-1-61779-243-4_17. PubMed PMID: 21796533.

Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer. 2011 Jun;2(3):145-56. doi: 10.1007/s12672-010-0063-1. PubMed PMID: 21761342; PubMed Central PMCID: PMC4467375.

Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol. 2011 Jul;179(1):400-10. doi: 10.1016/j.ajpath.2011.03.028. Epub 2011 May 4. PubMed PMID: 21703419; PubMed Central PMCID: PMC3123858.

Pascal LE, Ai J, Vêncio RZ, Vêncio EF, Zhou Y, Page LS, True LD, Wang Z, Liu AY. Differential Inductive Signaling of CD90 Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells. Cancer Microenviron. 2011 Jan 7;4(1):51-9. doi: 10.1007/s12307-010-0061-4. PubMed PMID:  21505567; PubMed Central PMCID: PMC3047627.

FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1196-203. doi: 10.1158/1055-9965.EPI-10-1299. Epub 2011 Apr 5. PubMed PMID: 21467234; PubMed Central PMCID: PMC3111761.

Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 2011 Nov;71(15):1631-7. doi: 10.1002/pros.21380. Epub 2011 Mar 22. PubMed PMID: 21432865; PubMed Central PMCID: PMC3409087.

Fesinmeyer MD, Kwon EM, Fu R, Ostrander EA, Stanford JL. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.  Prostate. 2011 Oct 1;71(14):1538-47. doi: 10.1002/pros.21370. Epub 2011 Feb 25. PubMed PMID: 21360564; PubMed Central PMCID: PMC3130811.

Zhau HE, He H, Wang CY, Zayzafoon M, Morrissey C, Vessella RL, Marshall FF, Chung LW, Wang R. Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res. 2011 Apr 15;17(8):2159-69. doi: 10.1158/1078-0432.CCR-10-2523. Epub 2011 Feb 25. PubMed PMID: 21355075; PubMed Central PMCID: PMC3085118.

Sprenger CC, Plymate SR, Reed MJ. Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression. Int J Cancer. 2010 Dec 15;127(12):2739-48. doi: 10.1002/ijc.25615. Epub 2010 Oct 8. Review. PubMed PMID: 21351253; PubMed Central PMCID: PMC3024458.

Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 2011 Apr 15;17(8):2301-13. doi: 10.1158/1078-0432.CCR-10-3077. Epub 2011 Feb 24. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4916. PubMed PMID: 21349995; PubMed Central PMCID: PMC4437585.

Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med. 2011 Mar;36(3):192-8. doi: 10.1097/RLU.0b013e318208f140. PubMed PMID: 21285676; PubMed Central PMCID: PMC3129631.

Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):619-27. doi: 10.1158/1055-9965.EPI-10-1023. Epub 2011 Jan 25. PubMed PMID: 21266523; PubMed Central PMCID: PMC3073610.

Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R, Fisher PB, Plymate SR, Wu JD. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene. 2011 May 19;30(20):2345-55. doi: 10.1038/onc.2010.605. Epub 2011 Jan 24. PubMed PMID: 21258401; PubMed Central PMCID: PMC3112005.

Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab. 2011 Feb;96(2):430-7. doi: 10.1210/jc.2010-1865. Epub 2010 Dec 22. PubMed PMID: 21177791; PubMed Central PMCID: PMC3048323.

Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010 Dec;120(12):4478-92. doi: 10.1172/JCI44239. Epub 2010 Nov 22. PubMed PMID: 21099110; PubMed Central PMCID:  PMC2993601.

Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, Stanford JL. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate. 2011 Apr;71(5):498-506. doi: 10.1002/pros.21267. Epub 2010 Oct 13. PubMed PMID: 20945498; PubMed Central PMCID: PMC3148811.

Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS, Lin DW. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res. 2010 Nov 15;16(22):5414-23. doi: 10.1158/1078-0432.CCR-10-0272. Epub 2010 Oct 8. PubMed PMID: 20935156; PubMed Central PMCID: PMC2992073.

Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010 Sep 15;70(13):1448-60. doi: 10.1002/pros.21180. PubMed PMID: 20687218; PubMed Central PMCID: PMC2927712.

Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19. PubMed PMID: 20644256; PubMed Central PMCID: PMC2912187.

Johanneson B, McDonnell SK, Karyadi DM, Quignon P, McIntosh L, Riska SM, FitzGerald LM, Johnson G, Deutsch K, Williams G, Tillmans LS, Stanford JL, Schaid DJ, Thibodeau SN, Ostrander EA. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet. 2010 Oct 1;19(19):3852-62. doi: 10.1093/hmg/ddq283. Epub 2010 Jul 14. PubMed PMID: 20631155; PubMed Central PMCID: PMC2935853.

Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate. 2010 Dec 1;70(16):1799-808. doi: 10.1002/pros.21216. PubMed PMID: 20583134; PubMed Central PMCID: PMC3104406.

Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate. 2010 Dec 1;70(16):1778-87. doi: 10.1002/pros.21214. PubMed PMID: 20583133; PubMed Central PMCID: PMC4403006.

True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, Ellis WJ, Liebeskind ES, Liu AY. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010 Oct;23(10):1346-56. doi: 10.1038/modpathol.2010.122. Epub 2010 Jun 18. PubMed PMID: 20562849; PubMed Central PMCID: PMC2948633.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL. CYP17 polymorphisms and prostate cancer outcomes. Prostate. 2010 Jul 1;70(10):1094-101. doi: 10.1002/pros.21143. PubMed PMID: 20503394; PubMed Central PMCID: PMC2878282.

Yu EY, Gulati R, Telesca D, Jiang P, Tam S, Russell KJ, Nelson PS, Etzioni RD, Higano CS. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol. 2010 Jun 1;28(16):2668-73. doi: 10.1200/JCO.2009.25.1330. Epub 2010 Apr 26. PubMed PMID: 20421544; PubMed Central PMCID: PMC2881848.

Schayek H, Seti H, Greenberg NM, Sun S, Werner H, Plymate SR. Differential regulation of insulin-like growth factor-I receptor gene expression by wild type and mutant androgen receptor in prostate cancer cells. Mol Cell Endocrinol. 2010 Jul 29;323(2):239-45. doi: 10.1016/j.mce.2010.04.017. Epub 2010 Apr 24. PubMed PMID: 20417685; PubMed Central PMCID: PMC2896981.

Fitzgerald LM, McDonnell SK, Carlson EE, Langeberg W, McIntosh LM, Deutsch K, Ostrander EA, Schaid DJ, Stanford JL. Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Genet. 2010 Oct;18(10):1141-7. doi: 10.1038/ejhg.2010.49. Epub 2010 Apr 21. PubMed PMID: 20407467; PubMed Central PMCID: PMC2921483.

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14. PubMed PMID: 20398925; PubMed Central PMCID: PMC2948179.

Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 2010 Apr 15;70(8):3239-48. doi: 10.1158/0008-5472.CAN-09-3186. Epub 2010 Apr 13. PubMed PMID: 20388787; PubMed Central PMCID: PMC2999007.

Mecham BH, Nelson PS, Storey JD. Supervised normalization of microarrays. Bioinformatics. 2010 May 15;26(10):1308-15. doi: 10.1093/bioinformatics/btq118. Epub 2010 Mar 31. PubMed PMID: 20363728; PubMed Central PMCID: PMC2865860.

Schayek H, Bentov I, Sun S, Plymate SR, Werner H. Progression to metastatic  stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res. 2010 May 15;316(9):1479-88. doi: 10.1016/j.yexcr.2010.03.007. Epub 2010 Mar 23. PubMed PMID: 20338164; PubMed Central PMCID: PMC2873092.

Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res. 2010 Apr;8(4):459-70. doi: 10.1158/1541-7786.MCR-09-0445. Epub 2010 Mar 23. PubMed PMID: 20332212; PubMed Central PMCID: PMC2946627.

Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 2010 Jun 15;70(9):1020-35. doi: 10.1002/pros.21137. PubMed PMID: 20209490; PubMed Central  PMCID: PMC2875326.

Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate  cancer risk in a population-based case-control study. Cancer Epidemiol. 2010 Apr;34(2):131-5. doi: 10.1016/j.canep.2010.02.003. Epub 2010 Mar 4. PubMed PMID: 20206591; PubMed Central PMCID: PMC2911123.

Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 2010 Mar 15;70(6):2307-17. doi: 10.1158/0008-5472.CAN-09-3252. Epub 2010 Mar 2. Erratum in: Cancer Res. 2011 Jul 15;71(14):5054. PubMed PMID: 20197463; PubMed Central PMCID: PMC4437589.

Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate. 2010 Jun 15;70(9):1012-9. doi: 10.1002/pros.21135. PubMed PMID: 20166135; PubMed Central PMCID: PMC2875316.

Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010 Apr;50(4):298-301. doi: 10.1016/j.ymeth.2010.01.032. Epub 2010 Feb 8. Erratum in: Methods. 2010 Nov;52(3):268. PubMed PMID: 20146939; PubMed Central PMCID: PMC4186708.

Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010 Feb 15;16(4):1088-93. doi: 10.1158/1078-0432.CCR-09-2917. Epub 2010 Feb 9. PubMed PMID: 20145158; PubMed Central PMCID: PMC2822877.

Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 2010 Apr;21(4):423-32. doi: 10.1097/CAD.0b013e328336f57b. PubMed PMID: 20130467; PubMed Central PMCID: PMC2953769.

Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia. 2010 Feb;12(2):192-205. PubMed PMID: 20126477; PubMed Central PMCID: PMC2814357.

Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS. Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 2010 Feb 15;70(4):1286-95. doi: 10.1158/0008-5472.CAN-09-2509. Epub 2010 Feb 2. PubMed PMID: 20124490; PubMed Central PMCID: PMC2822890.

Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LW, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res. 2010 Jan;8(1):119-30. doi: 10.1158/1541-7786.MCR-09-0277. Epub 2010 Jan 12. PubMed PMID: 20068069; PubMed Central PMCID: PMC2808437.

Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):258-64. doi: 10.1158/1055-9965.EPI-09-0800. PubMed PMID: 20056646; PubMed Central PMCID: PMC2825566.

Sprenger CC, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR. Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition. Clin Cancer Res. 2009 Dec 15;15(24):7634-7641. PubMed PMID: 19996218; PubMed Central PMCID: PMC2795132.

Wang D, Montgomery RB, Schmidt LJ, Mostaghel EA, Huang H, Nelson PS, Tindall DJ. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res. 2009 Dec 15;69(24):9448-56. doi: 10.1158/0008-5472.CAN-09-1903. PubMed PMID: 19934328; PubMed Central PMCID: PMC2795008.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077. PubMed PMID: 19866475; PubMed Central PMCID: PMC2931415.

Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate. 2010 Mar 1;70(4):412-24. doi: 10.1002/pros.21075. PubMed PMID: 19866469; PubMed Central PMCID: PMC2929015.

Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol. 2009 Dec;182(6):2702-7. doi: 10.1016/j.juro.2009.08.026. PubMed PMID: 19836772; PubMed Central PMCID: PMC2828768.

Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 2009 Oct 1;69(19):7793-802. doi: 10.1158/0008-5472.CAN-08-3810. Epub 2009 Sep 22. PubMed PMID: 19773449; PubMed Central PMCID: PMC2771763.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer

EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham  J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20. PubMed PMID: 19767753; PubMed Central PMCID: PMC2846760.

You H, Thomas G. A homeostatic switch in PACS-2 links membrane traffic to TRAIL-induced apoptosis. Cell Cycle. 2009 Sep 1;8(17):2679-80. Epub 2009 Sep 23. PubMed PMID: 19690460; PubMed Central PMCID: PMC4300122.

Takata Y, Morris JS, King IB, Kristal AR, Lin DW, Peters U. Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue. Prostate. 2009 Nov 1;69(15):1635-42. doi: 10.1002/pros.21012. PubMed PMID: 19623542; PubMed Central PMCID: PMC3166332.

Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer. 2009 Aug 15;115(16):3661-9. doi: 10.1002/cncr.24423. PubMed PMID: 19598210; PubMed Central PMCID: PMC2739798.

Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods. 2009 Jul;6(7):474-6. doi: 10.1038/nmeth0709-474. PubMed PMID: 19564845.

Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, Demichelis F, Freeman MR. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009 Jul 1;69(13):5601-9. doi: 10.1158/0008-5472.CAN-08-3860. Epub 2009 Jun 23. PubMed PMID: 19549916; PubMed Central PMCID: PMC2853876.

Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie G, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 1;69(13):5568-74. doi: 10.1158/0008-5472.CAN-09-0387. Epub 2009 Jun 23. PubMed PMID: 19549893; PubMed Central PMCID: PMC2884104.

Youker RT, Shinde U, Day R, Thomas G. At the crossroads of homoeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis. Biochem J. 2009 Jun 12;421(1):1-15. doi: 10.1042/BJ20081016. Review. PubMed PMID: 19505291; PubMed Central PMCID: PMC4303049.

Aslan JE, You H, Williamson DM, Endig J, Youker RT, Thomas L, Shu H, Du Y, Milewski RL, Brush MH, Possemato A, Sprott K, Fu H, Greis KD, Runckel DN, Vogel A, Thomas G. Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. Mol Cell. 2009 May 14;34(4):497-509. doi: 10.1016/j.molcel.2009.04.011. PubMed PMID: 19481529; PubMed Central PMCID: PMC2744858.

Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009 Jul 1;115(13):2863-71. doi: 10.1002/cncr.24324. PubMed PMID: 19466697; PubMed Central PMCID: PMC2948666.

Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1929-33. doi: 10.1158/1055-9965.EPI-09-0113. Epub 2009 May 19. PubMed PMID: 19454612; PubMed Central PMCID: PMC2743676.

Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol. 2009 May-Jun;27(3):251-7. doi: 10.1016/j.urolonc.2009.03.016. Review. PubMed PMID: 19414113; PubMed Central PMCID: PMC2705999.

Knouf EC, Metzger MJ, Mitchell PS, Arroyo JD, Chevillet JR, Tewari M, Miller AD. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol. 2009 Jul;83(14):7353-6. doi: 10.1128/JVI.00546-09. Epub 2009 Apr 29. PubMed PMID: 19403664; PubMed Central PMCID: PMC2704771.

Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res. 2009 May 1;15(9):3135-42. doi: 10.1158/1078-0432.CCR-08-1982. Epub 2009 Apr 14. PubMed PMID: 19366833; PubMed Central PMCID: PMC2929837.

Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res. 2009 May 1;15(9):3231-7. doi: 10.1158/1078-0432.CCR-08-2190. Epub 2009 Apr 14. PubMed PMID: 19366831; PubMed Central PMCID: PMC2707085.

Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 1;15(9):3223-30. doi: 10.1158/1078-0432.CCR-08-2733. Epub 2009 Apr 14. PubMed PMID: 19366828; PubMed Central PMCID: PMC2878092.

Harris JN, Bowen DJ, Kuniyuki A, McIntosh L, FitzGerald LM, Ostrander EA, Stanford JL. Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med. 2009 May;11(5):344-55. doi: 10.1097/GIM.0b013e31819b2425. PubMed PMID: 19346959; PubMed Central PMCID: PMC2683189.

Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. Review. PubMed PMID: 19275762; PubMed Central PMCID: PMC2921605.

Wu JD, Lin DW, Page ST, Lundgren AD, True LD, Plymate SR. Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol. 2009 Mar;2(1):39-45. PubMed PMID: 19252750; PubMed Central PMCID: PMC2647701.

Stanford JL, FitzGerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, Hood L, Ostrander EA, Schaid DJ. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009 May 15;18(10):1839-48. doi: 10.1093/hmg/ddp100. Epub 2009 Feb 27. PubMed PMID: 19251732; PubMed Central PMCID: PMC2671990.

Schenk JM, Neuhouser ML, Lin DW, Kristal AR. A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures. J Am Diet Assoc. 2009 Mar;109(3):459-63. doi: 10.1016/j.jada.2008.11.026. PubMed PMID: 19248862; PubMed Central PMCID: PMC3857024.

Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res. 2009 Mar 1;15(5):1558-65. doi: 10.1158/1078-0432.CCR-08-1440. Epub 2009 Feb 17. PubMed PMID: 19223505; PubMed Central PMCID: PMC2935172.

Lutz BR, Dentinger CE, Nguyen LN, Sun L, Zhang J, Allen AN, Chan S, Knudsen BS. Spectral analysis of multiplex Raman probe signatures. ACS Nano. 2008 Nov 25;2(11):2306-14. doi: 10.1021/nn800243g. PubMed PMID: 19206397; PubMed Central PMCID: PMC2662378.

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76-85. doi: 10.1038/ncpuro1296. Review. Erratum in: Nat Clin Pract Urol. 2009 Mar;6(3):173. PubMed PMID: 19198621; PubMed Central PMCID: PMC2981403.

Zhang X, Wang W, True LD, Vessella RL, Takayama TK. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis. Prostate. 2009 May 15;69(7):727-36. doi: 10.1002/pros.20920. PubMed PMID: 19170048; PubMed Central PMCID: PMC2720055.

Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, Vessella RL. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res. 2009 Jan 15;15(2):677-83. doi: 10.1158/1078-0432.CCR-08-1754. PubMed PMID: 19147774; PubMed Central PMCID: PMC3162324.

Parsons JK, Saria EA, Nakayama M, Vessella RL, Sawyers CL, Isaacs WB, Faith DA, Bova GS, Samathanam CA, Mitchell R, De Marzo AM. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate. 2009 Apr 1;69(5):559-69. doi: 10.1002/pros.20904. PubMed PMID: 19142959; PubMed Central PMCID: PMC2875878.

Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate. 2009 Mar 1;69(4):363-72. doi: 10.1002/pros.20887. PubMed PMID: 19058137; PubMed Central PMCID: PMC2788301.

Telesca D, Inoue LY, Neira M, Etzioni R, Gleave M, Nelson C. Differential expression and network inferences through functional data modeling. Biometrics. 2009 Sep;65(3):793-804. doi: 10.1111/j.1541-0420.2008.01159.x. Epub 2008 Nov 13. PubMed PMID: 19053995; PubMed Central PMCID: PMC2956129.

Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS  Biol. 2008 Dec 2;6(12):2853-68. doi: 10.1371/journal.pbio.0060301. PubMed PMID: 19053174; PubMed Central PMCID: PMC2592359.

O'Sullivan J, Sheridan J, Mulcahy H, Tenniswood M, Morrissey C. The effect of green tea on oxidative damage and tumour formation in Lobund-Wistar rats. Eur  J Cancer Prev. 2008 Nov;17(6):489-501. doi: 10.1097/CEJ.0b013e3282f0c04e. PubMed PMID: 18941371; PubMed Central PMCID: PMC4214214.

Holt SK, Salinas CA, Stanford JL. Vasectomy and the risk of prostate cancer. J Urol. 2008 Dec;180(6):2565-7; discussion 2567-8. doi: 10.1016/j.juro.2008.08.042. Epub 2008 Oct 19. PubMed PMID: 18930503; PubMed Central PMCID: PMC2582972.

Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):57-67. doi: 10.1097/PAI.0b013e3181816ae2. PubMed PMID: 18815565; PubMed Central PMCID: PMC2952101.

FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis. 2009;12(2):192-7. doi: 10.1038/pcan.2008.46. Epub 2008 Sep 2. PubMed PMID: 18762813; PubMed Central PMCID: PMC2790323.

Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel  W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners  JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; PRACTICAL Consortium, Eeles RA. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61. doi: 10.1158/1055-9965.EPI-08-0317. Erratum in: Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2901. Donovan, Jenny [added]; Hamdy, Freddie [added]. PubMed PMID: 18708398; PubMed Central PMCID: PMC2776652.

FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008 Aug 11;8:230. doi: 10.1186/1471-2407-8-230. PubMed PMID: 18694509; PubMed Central PMCID: PMC2519091.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28. PubMed PMID: 18663219; PubMed Central PMCID: PMC2492472.

Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008 Sep;180(3):1154-60. doi: 10.1016/j.juro.2008.04.140. Epub 2008 Jul 18. PubMed PMID: 18639279; PubMed Central PMCID: PMC2992811.

Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, Ellis WJ, True LD, Young JM, Hsu L, Trask BJ, Vessella RL. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008 Jul 15;68(14):5599-608. doi: 10.1158/0008-5472.CAN-08-0812. PubMed PMID: 18632612; PubMed Central PMCID: PMC2613025.

Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res. 2008 Jun 15;14(12):3823-31. doi: 10.1158/1078-0432.CCR-07-4566. PubMed PMID: 18559602; PubMed Central PMCID: PMC2675883.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249. PubMed PMID: 18519708; PubMed Central PMCID: PMC2536685.

Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):243-58. doi: 10.1016/j.beem.2008.01.003. Review. PubMed PMID: 18471783; PubMed Central PMCID: PMC2474812.

Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate. 2008 Jun 1;68(8):861-71. doi: 10.1002/pros.20752. PubMed PMID: 18361409; PubMed Central PMCID: PMC3162313.

Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 2008 Apr;36(7):2446-56. doi: 10.1093/nar/gkn089. Epub 2008 Feb 27. PubMed PMID: 18304946; PubMed Central PMCID: PMC2367734.

Knudsen BS, Allen AN, McLerran DF, Vessella RL, Karademos J, Davies JE, Maqsodi B, McMaster GK, Kristal AR. Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn. 2008 Mar;10(2):169-76. doi: 10.2353/jmoldx.2008.070127. Epub 2008 Feb 14. PubMed PMID: 18276773; PubMed Central PMCID: PMC2259472.

Hubbard RA, Inoue LY, Fann JR. Modeling nonhomogeneous Markov processes via time transformation. Biometrics. 2008 Sep;64(3):843-50. Epub 2007 Nov 19. PubMed PMID: 18047532.

Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008;25(4):377-88. Epub 2007 Oct 31. PubMed PMID: 17972146.

Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1990-9. PubMed PMID: 17932346.

Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control. 2008 Feb;19(1):25-31. Epub 2007 Sep 30. PubMed PMID: 17906959.

Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn. 2007 Sep;7(5):659-72. Review. PubMed PMID: 17892371.

Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. BMC Cancer. 2007 Aug 3;7:148. PubMed PMID: 17683568; PubMed Central PMCID: PMC2034387.

Agalliu I, Weiss NS, Lin DW, Stanford JL. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control. 2007 Nov;18(9):931-7. Epub 2007 Jul 20. PubMed PMID: 17641982.

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL,  Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20;25(15):2035-41. Erratum in: J Clin Oncol. 2007 Sep 10;25(26):4153. PubMed PMID: 17513807; PubMed Central PMCID: PMC2670394.

Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem. 2007 Jul 1;101(4):873-86. Review. PubMed PMID: 17387734.

Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007 Mar 15;109(6):1192-202. PubMed PMID: 17311344.

Tu LC, Yan X, Hood L, Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics. 2007 Apr;6(4):575-88. Epub 2007 Jan 12. PubMed PMID: 17220478.

Knudsen B. Migrating with myosin VI. Am J Pathol. 2006 Nov;169(5):1523-6. PubMed PMID: 17071577; PubMed Central PMCID: PMC1780205.

DeConde RP, Hawley S, Falcon S, Clegg N, Knudsen B, Etzioni R. Combining results of microarray experiments: a rank aggregation approach. Stat Appl Genet Mol Biol. 2006;5:Article15. Epub 2006 Jun 20. PubMed PMID: 17049026.

Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey E. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia. 2006 Oct;8(10):862-78. PubMed PMID: 17032503; PubMed Central PMCID: PMC1715921.

Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics. 2007 Jul;8(3):507-25. Epub 2006 Sep 15. PubMed PMID: 16980695.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 Sep 1;66(17):8337-41. PubMed PMID: 16951139.

Agalliu I, Lin DW, Salinas CA, Feng Z, Stanford JL. Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate. 2006 Oct 1;66(14):1535-41. PubMed PMID: 16921513.

True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6. Epub 2006  Jul 7. PubMed PMID: 16829574; PubMed Central PMCID: PMC1544162.

Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, Vessella RL. Telomerase activity in disseminated prostate cancer cells. BJU Int. 2006 Jun;97(6):1309-13. PubMed PMID: 16686730.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with

localized prostate cancer. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. PubMed PMID: 16145049.

Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol. 2005 Jul;167(1):255-66. PubMed PMID: 15972969; PubMed Central PMCID: PMC1603455.

Etzioni R, Hawley S, Billheimer D, True LD, Knudsen B. Analyzing patterns of staining in immunohistochemical studies: application to a study of prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1040-6. PubMed PMID: 15894650.

Hsu L, Self SG, Grove D, Randolph T, Wang K, Delrow JJ, Loo L, Porter P. Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics. 2005 Apr;6(2):211-26. PubMed PMID: 15772101.

Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004 Dec 1;64(23):8541-9. PubMed PMID: 15574760.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Metastases of prostate cancer express estrogen receptor-beta. Urology. 2004 Oct;64(4):814-20. PubMed PMID: 15491740.

Roudier MP, Corey E, True LD, Hiagno CS, Ott SM, Vessell RL. Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res. 2004;118:311-39. Review. PubMed PMID: 15043198.

Roudier MP, True LD, Vessella RL, Higano CS. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol. 2004 Mar;57(3):321-3. PubMed PMID: 14990610; PubMed Central PMCID: PMC1770231.

Abbott DE, Pritchard C, Clegg NJ, Ferguson C, Dumpit R, Sikes RA, Nelson PS. Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostate. Genome Biol. 2003;4(12):R79. Epub 2003 Nov 28. PubMed PMID: 14659016; PubMed Central PMCID: PMC329418.